

# **Xpert<sup>®</sup> Xpress MVP**

# **REF XPRSMVP-10**

**REF XPRSMVP-120** 

Instructions For Use



301-8994, Rev. F 11-2023

#### Trademark, Patents, and Copyright Statements

Cepheid<sup>®</sup>, the Cepheid logo, GeneXpert<sup>®</sup>, and Xpert<sup>®</sup> are trademarks of Cepheid, registered in the U.S. and other countries.

All other trademarks are the property of their respective owners.

THE PURCHASE OF THIS PRODUCT CONVEYS TO THE BUYER THE NON-TRANSFERABLE RIGHT TO USE IT IN ACCORDANCE WITH THESE INSTRUCTIONS FOR USE. NO OTHER RIGHTS ARE CONVEYED EXPRESSLY, BY IMPLICATION OR BY ESTOPPEL. FURTHERMORE, NO RIGHTS FOR RESALE ARE CONFERRED WITH THE PURCHASE OF THIS PRODUCT.

#### © 2022–2023 Cepheid.

See Section 26 for a description of changes.

# Xpert<sup>®</sup> Xpress MVP

Ronly

In Vitro Diagnostic Use

# **1 Proprietary Name**

Xpert® Xpress MVP

# 2 Common or Usual Name

Xpert Xpress MVP

# 3 Intended Use

The Xpert<sup>®</sup> Xpress MVP test, performed on the GeneXpert<sup>®</sup> Instrument Systems, is an automated qualitative *in vitro* diagnostic test for the detection of DNA targets from anaerobic bacteria associated with bacterial vaginosis (BV), *Candida* species associated with vulvovaginal candidiasis, and *Trichomonas vaginalis*. The Xpert Xpress MVP test uses clinician-collected and self-collected vaginal swabs (collected in a clinical setting) from patients who are symptomatic for vaginitis/ vaginosis. The Xpert Xpress MVP test utilizes real-time polymerase chain reaction (PCR) for the amplification of specific DNA targets and utilizes fluorogenic target-specific hybridization probes to detect and differentiate DNA from:

- Organisms associated with bacterial vaginosis (detected organisms not reported individually)
  - Atopobium spp. (Atopobium vaginae, Atopobium novel species CCUG 55226)
  - Bacterial Vaginosis-Associated Bacterium 2 (BVAB2)
  - Megasphaera-1
- Candida spp. (C. albicans, C. tropicalis, C. parapsilosis, C. dubliniensis, species not differentiated)
- Candida glabrata/Candida krusei (species not differentiated)
- Trichomonas vaginalis

The Xpert Xpress MVP test is intended to aid in the diagnosis of vaginal infections in women with a clinical presentation consistent with bacterial vaginosis, vulvovaginal candidiasis, or trichomoniasis.

# 4 Summary and Explanation

The most common causes of vaginosis and vaginitis are: 1) proliferation of one or more anaerobic bacterial species in the vaginal tract leading to vaginal discharge without inflammation (22–50% of symptomatic women), known as bacterial vaginosis; 2) vulvovaginal candidiasis (17–39%); and 3) trichomoniasis (4–35%).<sup>1</sup> Symptoms in undiagnosed women may be caused by a broad array of non-infectious conditions, including atrophic vaginitis, aerobic vaginitis, various vulvar dermatologic conditions, and vulvodynia. Abnormal vaginal discharge has a broad differential diagnosis, and successful treatment typically requires an accurate diagnosis.

# **5** Principle of the Procedure

The Xpert Xpress MVP test is an automated *in vitro* diagnostic test for qualitative detection of DNA targets from anaerobic bacteria associated with bacterial vaginosis, *Candida* species associated with vulvovaginal candidiasis, and *Trichomonas vaginalis*, the agent of trichomoniasis. The Xpert Xpress MVP test is performed on GeneXpert Instrument Systems.

The GeneXpert Instrument Systems automate and integrate sample preparation, nucleic acid extraction and amplification, and detection of the target sequences in simple or complex samples using real-time PCR tests. The systems consist of an instrument, computer, and preloaded software for running tests and viewing the results. The systems require the use of single-use disposable cartridges that hold the PCR reagents and host the PCR process. Because the cartridges are self-contained, cross-contamination between samples is minimized. For a full description of the system, see the relevant system operator manual.

The Xpert Xpress MVP test includes reagents for the detection of DNA from BV organisms, *Candida* species, and *Trichomonas vaginalis* from vaginal swab samples. A Sample Processing Control (SPC) and a Probe Check Control (PCC) are also included in the cartridge utilized by the GeneXpert System instrument. The SPC is present to control for adequate processing of the sample and to monitor for the presence of potential inhibitor(s) in the PCR. The SPC also ensures that the PCR conditions (temperature and time) are appropriate for the amplification reaction and that the PCR reagents are functional. The PCC verifies reagent rehydration, PCR tube filling, and confirms that all reaction components are present in the cartridge including monitoring for probe integrity and dye stability.

The Xpert Xpress MVP test is designed for use with the following specimens collected from symptomatic individuals: selfcollected vaginal swabs (collected in a clinical setting) and clinician-collected vaginal swabs. The swab transport reagent included in the Xpert Swab Specimen Collection Kit is designed to collect and preserve patient specimens to allow transport to the laboratory prior to analysis with the Xpert Xpress MVP test.

The specimen is briefly mixed by vigorously shaking the collection tube 3 to 4 times. Using the supplied transfer pipette, the sample is transferred to the sample chamber of the Xpert Xpress MVP cartridge. The GeneXpert cartridge is loaded onto the GeneXpert Instrument System platform, which performs hands-off, automated sample processing, and real-time PCR for the detection of DNA. Summary and detailed test results are obtained within 60 minutes and are displayed in tabular and graphic formats.

# 6 Materials Provided

The Xpert Xpress MVP 10-test kit (XPRSMVP-10) contains sufficient reagents to process 10 specimens or quality control samples and the Xpert Xpress MVP 120-test kit (XPRSMVP-120) contains sufficient reagents to process 120 specimens or quality control samples.

Each kit contains the following:

Xpert Xpress MVP cartridges with integrated reaction tubes	10 per kit	120 per kit	
• Bead 1, Bead 2, Bead 3 and Bead 4	1 of each per cartridge	1 of each per cartridge	
Lysis Reagent (Guanidinium thiocyanate)	1.3 mL per cartridge	1.3 mL per cartridge	
Sodium Hydroxide	0.44 mL per cartridge	0.44 mL per cartridge	
Binding Reagent	1.5 mL per cartridge	1.5 mL per cartridge	
Wash Reagent	0.48 mL per cartridge	0.48 mL per cartridge	
Elution Reagent	2.0 mL per cartridge	2.0 mL per cartridge	
Transfer Pipettes	12 per kit	144 per kit	
Instructions for Use	1 per kit	1 per kit	
CLIA Complexity: Waived			
(For use with the GeneXpert Xpress System only)			
Quick Reference Instructions	1 per kit	1 per kit	
CLIA Complexity: Waived			
(For use with the GeneXpert Xpress System only)			

	CD	1 per kit	1 per kit
	<ul> <li>Assay Definition File (ADF)</li> <li>Instructions to import ADF into GeneXpert software</li> <li>Instructions for Use</li> </ul>		
oto	Safety Data Sheets (SDS) are available at www.cepheid.cor	n or www.cepheidinternational.	com under the SUPPORT

Note Safety Data Sheets (SDS) are available at www.cepneid.com or www.cepneidinternational.com under the Community tab.

Note The bovine serum albumin (BSA) in the beads within this product was produced and manufactured exclusively from bovine plasma sourced in the United States. No ruminant protein or other animal protein was fed to the animals; the animals passed ante- and post-mortem testing. During processing, there was no mixing of the material with other animal materials.

### 7 Storage and Handling

- Store the Xpert Xpress MVP cartridges at 2–28°C until the expiration date provided on the label.
- Do not use expired cartridges.
- Do not open a cartridge lid until you are ready to perform testing.
- Do not use a cartridge that is wet or has leaked.
- Do not open or alter any part of the used cartridge for disposal.

# 8 Materials Required but not Provided

- Samples must be collected and transported with the Xpert Swab Specimen Collection kit (catalog number SWAB/G-50-US).
- GeneXpert Dx instrument or GeneXpert Infinity Systems (catalog number varies by configuration): GeneXpert instrument, computer, barcode scanner, operator manual.
  - For GeneXpert Dx System: GeneXpert Dx software version 4.7b or higher
  - For GeneXpert Infinity-80 and Infinity-48s systems: Xpertise software version 6.4b or higher

### 9 Warnings and Precautions

### 9.1 General

- For *in vitro* diagnostic use.
- For prescription use only.
- Treat all biological samples, including used cartridges, as if capable of transmitting infectious agents. Because it is often impossible to know which might be infectious, all biological samples should be handled using standard precautions. Guidelines for sample handling are available from the U.S. Centers for Disease Control and Prevention<sup>2</sup> and the Clinical and Laboratory Standards Institute.<sup>3</sup>
- Follow safety procedures set by your institution for working with chemicals and handling biological samples.
- Consult your institution's environmental waste personnel on proper disposal of used cartridges, which may contain
  amplified material. This material may exhibit characteristics of Federal EPA Resource Conservation and Recovery Act
  (RCRA) hazardous waste requiring specific disposal requirements. Check state and local regulations as they may differ
  from federal disposal regulations. Institutions should check the hazardous waste disposal requirements within their
  respective countries.
- Do not open or alter any part of the used cartridge for disposal.

### 9.2 Specimen

- For collection and transport of vaginal swab samples, use only the Xpert Swab Specimen Collection Kit.
- Vaginal swab samples must be collected and tested before the expiration date printed on the Xpert Swab Specimen Collection Kit.
- Maintain proper storage conditions during sample transport to ensure the integrity of the sample (see Section 11).
   Samples placed in transport medium following collection can be stored for up to 42 days at 2–28°C. Sample stability under shipping/storage conditions other than those recommended has not been evaluated.

### 9.3 Assay/Reagent

- Do not open the Xpert Xpress MVP cartridge lid except when adding specimen.
- Do not use a cartridge that has been dropped after removing it from the packaging.
- Do not shake the cartridge. Shaking or dropping the cartridge after opening the cartridge may yield non-determinate results.
- Do not place the sample ID label on the cartridge lid or on the barcode label.
- Do not use a cartridge with a damaged or missing barcode label.
- Do not use a cartridge that has a damaged or missing reaction tube.
- Each single-use Xpert Xpress MVP cartridge is used to process one test. Do not reuse processed cartridges.
- Each single-use disposable pipette is used to transfer one specimen. Do not reuse disposable pipettes.
- Do not use a cartridge if it appears wet or if the lid seal appears to have been broken.
- Wear clean lab coats and gloves. Change gloves between the handling of each specimen.
- In the event of a spill of specimens or controls, wear gloves and absorb the spill with paper towels. Then, thoroughly clean the contaminated area with a 1:10 dilution of freshly prepared household chlorine bleach. Final active chlorine concentration should be 0.5% regardless of the household bleach concentration in your country. Allow a minimum of two minutes of contact time. Ensure the work area is dry before using 70% denatured ethanol to remove bleach residue. Allow surface to dry completely before proceeding. Or, follow your institution's standard procedures for a contamination or spill event. For equipment, follow the manufacturer's recommendations for decontamination of equipment.
- Biological specimens, transfer devices, and used cartridges should be considered capable of transmitting infectious agents requiring standard precautions. Follow your institution's environmental waste procedures for proper disposal of used cartridges and unused reagents. These materials may exhibit characteristics of chemical hazardous waste requiring specific disposal. If country or regional regulations do not provide clear direction on proper disposal, biological specimens and used cartridges should be disposed per WHO [World Health Organization] medical waste handling and disposal guidelines.

# 10 Chemical Hazards<sup>4</sup>

- UN GHS Signal Word: Warning
- UN GHS Hazard Statements:
  - May be harmful if swallowed.
  - May be harmful in contact with skin.
  - Causes eye irritation.
- UN GHS Hazard Statements:
  - Prevention
    - Wash thoroughly after handling.
  - Response
    - Call a POISON CENTER or doctor/physician if you feel unwell.
    - If skin irritation occurs: Get medical advice/attention.
    - IF IN EYES: Rinse cautiously with water for several minutes. Remove contact lenses, if present and easy to do. Continue rinsing.
    - If eye irritation persists: Get medical advice/attention.

# 11 Specimen Collection, Transport, and Storage

- Proper sample collection, storage, and transport are critical to the performance of this test. Inadequate sample collection, improper sample handling and/or transport may yield a false result. Samples should be transported at 2–28°C.
- Samples placed in transport medium following collection can be stored for up to 42 days at 2–28°C prior to testing with the Xpert Xpress MVP test.
- Refer to the Xpert Swab Specimen Collection Kit Instructions for Use for collection and transport instructions.

# **12 Procedure**

### 12.1 Preparing the Cartridge

#### Important Start the test within 30 minutes of adding the sample to the cartridge.

- 1. Obtain a new Xpert Xpress MVP cartridge and a new transfer pipette provided in the Xpert Xpress MVP test kit.
- 2. Open the cartridge by lifting the front of the cartridge lid.
- 3. Check that the specimen transport tube cap is closed. Vigorously shake the specimen transport tube 3 to 4 times.

Note Not shaking or inadequate shaking of the specimen transport tube may generate false negative results.

- 4. Open the lid on the specimen transport tube.
- 5. Remove the transfer pipette from the wrapper.
- 6. Squeeze the top bulb of the transfer pipette **completely until the top bulb is fully flat**. While continuing to hold the bulb fully flat, place the pipette tip in the specimen transport tube (see Figure 1).




Figure 1. Transfer Pipette

Number	Description
1	Top Bulb (Squeeze here until fully flat)
2	Overflow Reservior Bulb (Do Not Squeeze)
3	Pipette
4	Sample

- 7. Keeping the pipette below the surface of the liquid, release the top bulb of the pipette **slowly until the pipette is completely filled with sample** before removing from the tube. After filling pipette, excess sample may be seen in the overflow reservoir bulb of the pipette (see Figure 1). It is okay if liquid goes into the overflow reservoir. Check that the pipette does not contain bubbles.
- 8. To transfer the sample to the cartridge, put the pipette into the large opening on the lower right corner of the cartridge (see green arrow on sample chamber) shown in Figure 2. Squeeze the top bulb of the transfer pipette **completely until** it is fully flat to empty the contents.



#### Figure 2. Xpert Xpress MVP Cartridge

- 9. Continue to hold the top bulb fully flat and do not release until the pipette is removed from the cartridge. Do not reuse a pipette. Dispose of the used pipette in an appropriate waste container after use.
- **Note** Take care to dispense the entire volume of liquid from the transfer pipette into the sample chamber. Non-determinate results may occur if insufficient sample is added to the cartridge.
  - 10. Close the cartridge lid.

Note Time to result is within 60 minutes.

### **12.2 External Controls**

Use external control materials in accordance with local, state, federal regulations, and accreditation requirements.

To run a control using the Xpert Xpress MVP test:

- 1. Have a new Xpert Xpress MVP test cartridge, a transfer pipette provided in the Xpert Xpress MVP test kit, and a quality control tube ready.
- 2. Open the cartridge lid.
- 3. Vigorously shake the external control sample 3 to 4 times.
- 4. Using a clean transfer pipette, squeeze the top bulb of the transfer pipette completely until the top bulb is fully flat. While continuing to hold the bulb fully flat, place the pipette tip in the external control tube (see Figure 1). Keeping the pipette below the surface of the liquid, release the top bulb of the pipette slowly until the pipette is completely filled with sample before removing it from the tube. Check that the pipette does not contain bubbles.
- 5. Squeeze the top bulb of the transfer pipette completely again to empty the contents of the pipette into the large opening (Sample Chamber) in the cartridge shown in Figure 2. Continue to hold the top bulb fully flat and do not release until the pipette is removed from the cartridge. Dispose of the used pipette.
- 6. Close the cartridge lid.

# 13 Running the Test

- For the GeneXpert Dx System, see Section 13.1.
- For the GeneXpert Infinity System, see Section 13.2.

### 13.1 GeneXpert Dx System

#### 13.1.1 Starting the Test

#### Before you start the test, make sure that:

Important
The system is running the correct GeneXpert Dx software version shown in section - Materials Required but Not Provided.
The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the *GeneXpert Dx System Operator Manual*.

Note The steps you follow can be different if the system administrator changed the default workflow of the system.

- 1. Turn on the GeneXpert Dx System, then turn on the computer and log on. The GeneXpert software will launch automatically. If it does not, double-click the GeneXpert Dx software shortcut icon on the Windows<sup>®</sup> desktop.
- 2. Log on using your username and password.
- 3. In the GeneXpert System window, click Create Test. The Create Test window displays. The Scan Patient ID barcode dialog box displays.
- 4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the View Results window and all the reports. The Scan Sample ID barcode dialog box displays.
- Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the View Results window and all the reports. The Scan Cartridge Barcode dialog box displays.
- 6. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

- 7. Click Start Test. In the dialog box that displays, type your password, if required.
- 8. Open the instrument module door with the blinking green light and load the cartridge.
- 9. Close the door. The test starts and the green light stops blinking.

When the test is finished, the light turns off.

- 10. Wait until the system releases the door lock before opening the module door, then remove the cartridge.
- 11. Dispose of the used cartridges in the appropriate specimen waste containers according to your institution's standard practices.

**Note** Do not turn off or unplug the instrument while a test is in progress. Turning off or unplugging the instrument or computer will stop the test.

#### 13.1.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Dx System Operator Manual*.

- 1. Click the **View Results** icon to view results.
- 2. Upon completion of the test, click the **Report** button of the **View Results** window to view and/or generate a PDF report file.

### 13.2 GeneXpert Infinity System

#### 13.2.1 Starting the Test

#### Before you start the test, make sure that:

Important • The system is running the correct Xpertise software version shown in section - Materials Required but Not Provided.

• The correct assay definition file is imported into the software.

This section lists the basic steps for running the test. For detailed instructions, see the *GeneXpert Infinity System Operator Manual*.

Note The steps you follow can be different if the system administrator changed the default workflow of the system.

- 1. Power up the instrument. The Xpertise software will launch automatically. If it does not, double-click the Xpertise software shortcut icon on the Windows<sup>®</sup> desktop.
- 2. Log on to the computer, then log on to the GeneXpert Xpertise software using your user name and password.
- 3. In the Xpertise Software Home workspace, click Orders and in the Orders workspace, click Order Test. The Order Test - Patient ID workspace displays.
- 4. Scan or type in the Patient ID. If typing the Patient ID, make sure the Patient ID is typed correctly. The Patient ID is associated with the test results and displays in the **View Results** window and all the reports.
- 5. Enter any additional information required by your institution, and click the **CONTINUE** button. The **Order Test Sample ID** workspace displays.
- 6. Scan or type in the Sample ID. If typing the Sample ID, make sure the Sample ID is typed correctly. The Sample ID is associated with the test results and displays in the **View Results** window and all the reports.
- Click the CONTINUE button. The Order Test - Assay workspace displays.
- 8. Scan the barcode on the cartridge. Using the barcode information, the software automatically fills the boxes for the following fields: Select Assay, Reagent Lot ID, Cartridge SN, and Expiration Date.

If the barcode on the cartridge does not scan, then repeat the test with a new cartridge. If you have scanned the cartridge barcode in the software and the assay definition file is not available, a screen displays indicating the assay definition file is not loaded on the system. If this screen displays, contact Cepheid Technical Support.

After the cartridge is scanned, the **Order Test - Test Information** workspace displays.

- 9. Verify that the information is correct, and click **Submit**. In the dialog box that displays, type your password, if required.
- **10.** Place the cartridge on the conveyor belt.

**Note** Do not turn off or unplug the system while a test is in progress. Turning off or unplugging the GeneXpert instrument or computer will stop the test.

The cartridge automatically loads, the test runs, and the used cartridge are placed into the waste container.

#### 13.2.2 Viewing and Printing Results

This section lists the basic steps for viewing and printing results. For more detailed instructions on how to view and print the results, see the *GeneXpert Infinity System Operator Manual*.

- 1. In the Xpertise Software Home workspace, click the RESULTS icon. The Results menu displays.
- 2. In the Results menu, select the VIEW RESULTS button. The View Results workspace displays showing the test results.
- 3. Click the **REPORT** button to view and/or generate a PDF report file.

# **14 Quality Control**

Each test includes a Sample Processing Control (SPC) and Probe Check Control (PCC).

**Sample Processing Control (SPC)** – Ensures that the sample is processed correctly. The SPC verifies that sample processing is adequate. Additionally, this control detects sample-associated inhibition of the real-time PCR test, ensures that the PCR conditions (temperature and time) are appropriate for the amplification reaction, and that the PCR reagents are functional. The SPC should be positive in a negative sample and can be negative or positive in a positive sample. The SPC passes if it meets the validated acceptance criteria.

**Probe Check Control (PCC)** – Before the start of the PCR, the GeneXpert System measures the fluorescence signal from the probes to monitor bead rehydration, reaction tube filling, probe integrity, and dye stability. The PCC passes if it meets the validated acceptance criteria.

# **15 Interpretation of Results**

The results are interpreted automatically by the GeneXpert System and are clearly shown in the **View Results** window. Some of the possible results and interpretations are shown in Table 1; additional combinations of results are possible and likely to occur.

Result	Interpretation
BV NEGATIVE Candida group NOT DETECTED Candida glab-krus NOT DETECTED TV NOT DETECTED	<ul> <li>Indicator DNA target(s) related to bacterial vaginosis (BV) organisms is/are not detected (see Table 2); Candida group (<i>C. albicans</i> and/or <i>C. tropicalis</i> and/or <i>C. parapsilosis</i> and/or <i>C. dubliniensis</i>) target DNA is not detected; Candida glab-krus (<i>Candida glabrata</i> and/or <i>C. krusei</i>) target DNA is not detected; and <i>Trichomonas vaginalis</i> (TV) target DNA is not detected.</li> <li>SPC: PASS; SPC has a Ct within the valid range and endpoint above the threshold setting.</li> <li>PCC: PASS; all probe check results pass.</li> </ul>
BV POSITIVE Candida group DETECTED Candida glab-krus DETECTED TV DETECTED	<ul> <li>Indicator DNA target(s) related to bacterial vaginosis (BV) organisms is/are detected (see Table 2); Candida group (<i>C. albicans</i> and/or <i>C. tropicalis</i> and/or <i>C. parapsilosis</i> and/or <i>C. dubliniensis</i>) target DNA is detected; Candida glab-krus (<i>Candida glabrata</i> and/or <i>C. krusei</i>) target DNA is detected; and <i>Trichomonas vaginalis</i> (TV) target DNA is detected.</li> <li>BV, Candida group, Candida glab-krus, and TV: Ct values are within the valid range.</li> <li>SPC: NA (not applicable); SPC signal is not part of the result interpretation algorithm if the target DNA is detected since SPC signal may be suppressed due to competition with BV, Candida glab-krus, and TV targets.</li> <li>PCC: PASS; all probe check results pass.</li> </ul>
INVALID	<ul> <li>Presence or absence of the target DNA cannot be determined.</li> <li>BV, Candida group, Candida glab-krus, and TV: one or more of the analyte results is INVALID.</li> <li>SPC: FAIL or NA.</li> <li>PCC: PASS; all probe check results pass.</li> <li>Note If SPC shows NA, the INVALID may be caused by a test parameter failure.</li> <li>Repeat test according to the instructions in Section 16.2.</li> </ul>

#### Table 1. Xpert Xpress MVP Results and Interpretations

Result	Interpretation				
ERROR	<ul> <li>Presence or absence of BV, Candida group, Candida glab-krus, and TV target DNA cannot be determined</li> <li>BV, Candida group, Candida glab-krus, and TV: NO RESULT</li> <li>SPC: NO RESULT</li> <li>PCC: FAIL; all or one of the probe check results fail.</li> </ul>				
	Note If the probe check passes or shows NA, the error may be caused by the maximum pressure limit exceeding the acceptable range, insufficient sample volume or by a system component failure.				
	Repeat test according to the instructions in Section 16.2.				
NO RESULT	Presence or absence of BV, Candida group, Candida glab-krus, and TV target DNA cannot be determined. A <b>NO RESULT</b> indicates that insufficient data were collected. For example, cartridge integrity test failed, the operator stopped a test that was in progress or a power failure occurred.				
	<ul> <li>BV, Candida group, Candida glab-krus, and TV: NO RESULT</li> <li>SPC: NO RESULT</li> <li>PCC: NA (not applicable)*</li> </ul>				
	If the probe check shows NA, the error may be caused by the maximum pressure limit exceeding the acceptable range and terminates the run prior to probe check.				
	Repeat test according to the instructions in Section 16.2.				

Table 2 presents the BV algorithm and the expected results.

### Table 2. BV Results Algorithm<sup>a</sup>

	BV Result		
Atopobium spp. <sup>b</sup>			
+	+	-	BV Positive
+	-	+	BV Positive
+	+	+	BV Positive
+ (high concentration)	-	-	BV Positive
-	+/-	+/-	BV Negative

a Algorithm results are either BV positive or BV negative.

<sup>b</sup> Atopobium vaginae and/or Atopobium novel species CCUG 55226.

# 16 Retests

### 16.1 Reasons to Repeat the Test

If any of the test results mentioned below occur, repeat the test once according to instructions in Section 16.2.

- An **INVALID** result indicates that the control SPC failed or a test parameter failed. The sample was not properly processed, PCR was inhibited, or the sample was not properly collected.
- An **ERROR** result could be due to, but not limited to, Probe Check Control failure, system component failure, insufficient sample volume, or the maximum pressure limits were exceeded.
- A **NO RESULT** indicates that insufficient data were collected. For example, cartridge failed integrity test, the operator stopped a test that was in progress, or a power failure occurred.

If an External Control fails to perform as expected, repeat external control test and/or contact Cepheid Technical Support for assistance.

### 16.2 Retest Procedure

To retest an INVALID, NO RESULT, or ERROR result (non-determinate result), use a new cartridge.

Use the leftover sample from the original specimen transport tube.

- 1. Put on a clean pair of gloves. Obtain a new Xpert Xpress MVP cartridge and a transfer pipette provided in the Xpert Xpress MVP test kit.
- 2. Mix the sample by vigorously shaking the specimen transport tube 3 to 4 times. Open the cap on the specimen transport tube.
- 3. Open the cartridge lid.
- 4. Using a clean transfer pipette (supplied), transfer sample (one draw) to the sample chamber with the large opening in the cartridge.
- 5. Dispose of the used cartridge and gloves in an appropriate sample waste container according to your institution's standard practices.

# **17 Limitations**

- The Xpert Xpress MVP test has been validated using only the procedures provided in this Instructions for Use. Modification to these procedures may alter the performance of the test.
- The Xpert Xpress MVP test has been validated with vaginal swabs collected with the Xpert Swab Specimen Collection Kit.
- Testing of vaginal swab specimens with the Xpert Xpress MVP test is not intended to replace an exam by a clinician. Vaginal infections may result from other causes or concurrent infections may occur.
- As with many diagnostic tests, results from the Xpert Xpress MVP test should be interpreted in conjunction with other laboratory and clinical data available to the clinician.
- Public health recommendations should be consulted regarding testing for additional sexually transmitted diseases for patients with a positive result for bacterial vaginosis (BV) or *T. vaginalis* with the Xpert Xpress MVP test.
- The Xpert Xpress MVP test targets three anaerobic microorganisms that are associated with BV. Other organisms that are not detected by the Xpert Xpress MVP test have also been reported to be associated with BV and aerobic vaginitis.
- A Candida group positive result can be due to one or multiple *Candida* species.
- *Candida* species can be present as commensal organisms in women; the Xpert Xpress MVP positive results for *Candida* should be considered in conjunction with other clinical and patient information to determine the disease status.
- The BV organism targets of the Xpert Xpress MVP test can be commensal in women; Xpert Xpress MVP positive results for bacterial vaginosis should be considered in conjunction with other clinical and patient information to determine the disease status.
- Erroneous test results might occur from improper specimen collection, technical error, sample mix-up, or because the number of organisms in the specimen is not detected by the test. Careful compliance with the instructions in this Instructions for Use and the Xpert Swab Specimen Collection Kit instruction documents are necessary to avoid erroneous results.

- A negative test result does not exclude the possibility of infection because test results may be affected by improper specimen collection, technical error, specimen mix-up, concurrent antibiotic therapy, or the number of organisms in the specimen that may be below the sensitivity of the tests.
- False negative results may occur if the organism(s) is present at levels below the analytical limit of detection below the cut-off concentration or outside the BV algorithm parameters for a positive result.
- Mutations or other changes within the regions of the microbial genomes covered by the primers and/or probes in the Xpert Xpress MVP test may result in failure to detect the target organisms.
- The effects of other potential variables such as vaginal discharge, use of tampons, douching, and specimen collection variables have not been determined.
- The Xpert Xpress MVP test provides qualitative results. No correlation can be drawn between the magnitude of the Ct value and the number of cells in an infected sample.
- The Xpert Xpress MVP test performance has been evaluated in patients 14 years of age and older (including pregnant women).
- The Xpert Xpress MVP test has not been validated for use with vaginal swab specimens collected by patients at home. The self-collected vaginal swab specimen application is limited to healthcare facilities where support/counseling is available to explain procedures and precautions.
- Five strains of *Candida albicans* evaluated in the Inclusivity Study were detected by the Xpert Xpress MVP test. Three of the strains were only detected at concentrations higher than 3× LoD (one strain at 4× LoD and two strains at 20× LoD).
- Eleven strains of *Atopobium* spp. evaluated in the Inclusivity Study were detected by the Xpert Xpress MVP test. Four of the strains were only detected at concentrations higher than 3× near cut-off concentration (ranging from 4× and 12×).
- *Candida orthopsilosis*, a recently described species that has been grouped previously with *C. parapsilosis*, was found to cross-react with the Xpert Xpress MVP test at levels above 1×10<sup>2</sup> CFU/mL. *Pentatrichomonas hominis* (a commensal of the large intestine) was found to cross-react with the Xpert Xpress MVP test at levels above 5×10<sup>4</sup> cells/mL. *Trichomonas tenax* (a commensal of the oral cavity) was found to cross-react with the Xpert Xpress MVP test at levels above 10 cells/mL. See Section 20.3 for details.
- Interference with the Xpert Xpress MVP test was observed in the presence of mucin (from porcine stomach) (≥5.5% v/v). See Section 20.6 for details.
- The analyte target may persist *in vivo*, independent of pathogen viability. Detection of the analyte target does not imply that the corresponding pathogen is infectious, or is the causative agent of the clinical symptoms.
- The Xpert Xpress MVP test cannot be used to assess therapeutic success or failure since target nucleic acids may persist following antimicrobial therapy.

# **18 Expected Values**

Positivity rates in the symptomatic patient population, as observed in the clinical study determined by the Xpert Xpress MVP test, were calculated from clinician-collected vaginal swab (CVS) and self-collected vaginal swab (SVS) specimens and are presented by target and by race/ethnicity in Table 3.

			Black /Africa	an American	White			
	Target	Overall	Hispanic/ Latino	Not Hispanic/ Latino	Hispanic/ Latino	Not Hispanic/ Latino	Asian	Others <sup>a</sup>
	BV	40.9%	62.5%	59.5%	37.7%	24.9%	23.8%	50.0%
	DV	(588/1436)	(10/16)	(327/550)	(72/191)	(154/618)	(5/21)	(20/40)
	Candida	31.2%	43.8%	34.4%	32.0%	27.9%	31.8%	31.0%
CVS	group	(453/1450)	(7/16)	(191/555)	(62/194)	(173/621)	(7/22)	(13/42)
ΰ	Candida glab-krus	3.4%	0%	4.1%	3.1%	3.1%	0%	2.4%
		(49/1450)	(0/16)	(23/555)	(6/194)	(19/621)	(0/22)	(1/42)
	τv	5.5%	0%	11.4%	2.7%	1.6%	0%	2.5%
		(78/1423)	(0/16)	(62/545)	(5/188)	(10/613)	(0/21)	(1/40)
	BV	41.8%	62.5%	59.4%	37.5%	26.7%	30.0%	52.6%
		(598/1431)	(10/16)	(325/547)	(72/192)	(165/618)	(6/20)	(20/38)
	Candida	32.9%	37.5%	35.7%	34.4%	30.3%	28.6%	30.0%
SVS	group	(476/1445)	(6/16)	(197/552)	(67/195)	(188/621)	(6/21)	(12/40)
Ś	Candida	3.7%	0%	4.2%	3.1%	3.9%	0%	2.5%
	glab-krus	(54/1445)	(0/16)	(23/552)	(6/195)	(24/621)	(0/21)	(1/40)
	TV	5.3%	0%	4.2%	2.6%	1.5%	0%	2.6%
		(75/1418)	(0/16)	(23/542)	(5/189)	(9/613)	(0/20)	(1/38)

Table 3.	Positivity	Rates	in S	ymptomatic	Patients
	1 03101111	Trates		ymptomatio	i unomo

<sup>a</sup> Including: American Indian or Alaska Native, Native Hawaiian or Other Pacific Islander, Mixed/Unknown

Although the Xpert Xpress MVP test is not intended for use in an asymptomatic patient population, positivity rates were calculated from CVS and SVS specimens collected from asymptomatic patients to assess how often patients who, despite being asymptomatic, harbored microbial flora associated with vaginosis and candidiasis that could be detected by the Xpert Xpress MVP test. Positivity rates are presented by target and by race/ethnicity in Table 4.

		Overall Black /African American <sup>a</sup>	Black /African	Wh		
	Target		Hispanic/Latino	Not Hispanic/ Latino	Others <sup>b</sup>	
	BV	32.9% (52/158)	51.0% (26/51)	25.5% (14/55)	19.5% (8/41)	36.4% (4/11)
CVS	Candida group	17.1% (27/158)	25.5% (13/51)	16.4% (9/55)	7.3%	18.2%
	Candida glab-krus	4.4% (7/158)	2.0% (1/51)	5.5% (3/55)	4.9% (2/41)	9.1% (1/11)

			Black /African	Wh		
	Target	Overall American <sup>a</sup>	Hispanic/Latino	Not Hispanic/ Latino	Others <sup>b</sup>	
SVS	BV	31.5% (51/162)	49.1% (26/53)	24.1% (13/54)	16.3% (7/43)	41.7% (5/12)
	Candida group	19.1% (31/162)	28.3% (15/53)	18.5% (10/54)	7.0% (3/43)	25.0% (3/12)
	Candida glab-krus	4.9% (8/162)	1.9% (1/53)	7.4% (4/54)	4.7% (2/43)	8.3% (1/12)

<sup>a</sup> Includes one Black/African American who was of Hispanic or Latino descent for CVS specimens; includes two Black/African Americans who were of Hispanic or Latino descent for SVS specimens.

<sup>b</sup> Including: American Indian or Alaska Native, Asian, Mixed/Unknown

# **19 Performance Characteristics**

### **19.1 Clinical Performance**

A blinded clinical study was conducted to evaluate the performance of the Xpert Xpress MVP test at 12 geographically diverse sites in the U.S. Subjects included female patients  $\geq$  14 years of age who presented with signs and/or symptoms of vaginosis/vaginitis. For eligible subjects, one (1) self-collected (collected in a clinical setting, SVS) and five (5) clinician-collected vaginal swab (CVS) specimens were obtained for testing with the Xpert Xpress MVP test and reference/ comparator testing. Patient management continued at the site per the standard practice, independent of investigational test results.

The Xpert Xpress MVP test performance was compared to the following reference/comparator methods: an FDA-cleared nucleic acid amplification test (NAAT) for the BV target, yeast culture followed by mass spectrometry identification for the Candida group and Candida glab-krus targets, a patient infected status (PIS) algorithm that included a combination of NAAT and culture results for the TV target. When applicable, investigation of discrepant results was performed by testing specimens with another FDA-cleared NAAT.

### 19.2 Results

The study population comprised of 1,476 female patients 18 to  $\geq$  50 years of age. Additionally, two patients between 14–17 years of age were enrolled in the study. A total of 2,947 vaginal swabs (1473 CVS and 1474 SVS specimens) were tested and were eligible for inclusion in the Xpert Xpress MVP study.

Performance of the Xpert Xpress MVP test is presented in Table 5. The Xpert Xpress MVP test demonstrated positive percent agreement (PPA) and negative percent agreement (NPA) of 93.8% and 93.8% for BV detection in CVS specimens, respectively, and 94.0% and 92.9% in SVS specimens, respectively. For Candida group detection, the Xpert Xpress MVP test demonstrated sensitivity and specificity of 98.0% and 94.6% in CVS specimens, respectively, and 97.5% and 92.1% in SVS specimens, respectively. The Xpert Xpress MVP test demonstrated sensitivity and specificity of 98.0% and 94.6% in CVS specimens, respectively, and 97.5% and 92.1% in SVS specimens, respectively. The Xpert Xpress MVP test demonstrated sensitivity and specificity of 93.6% and 99.6% for Candida glab-krus detection in CVS specimens, respectively, and 97.8% and 99.4% in SVS specimens, respectively. For TV detection, the Xpert Xpress MVP test demonstrated PPA and NPA of 97.3% and 99.6% in CVS specimens, respectively, and 97.3% and 99.8% in SVS specimens, respectively.

	Clinician-collected (CVS)		Self-colled	cted (SVS)
	Sensitivity/PPA (95% Cl)	Specificity/NPA (95% Cl)	Sensitivity/PPA (95% Cl)	Specificity/NPA (95% Cl)
	93.8%	93.8%	94.0%	92.9%
BV	531/566 <sup>a</sup>	808/861 <sup>b</sup>	533/567 <sup>c</sup>	794/855 <sup>d</sup>
	(91.5% - 95.5%)	(92.0% - 95.3%)	(91.7% - 95.7%)	(90.9% - 94.4%)
	98.0%	94.6%	97.5%	92.1%
Candida group <sup>e</sup>	396/404 <sup>f</sup>	984/1040 <sup>g</sup>	393/403 <sup>h</sup>	954/1036 <sup>i</sup>
	(96.1% - 99.0%)	(93.1% - 95.8%)	(95.5% - 98.7%)	(90.3% - 93.6%)
	93.6%	99.6%	97.8%	99.4%
Candida glab-krus Fresh Prospective	44/47 <sup>j</sup>	1392/1397 <sup>k</sup>	45/46 <sup>1</sup>	1384/1393 <sup>m</sup>
	(82.8% - 97.8%)	(99.2% - 99.9%)	(88.7% - 99.6%)	(98.8% - 99.7%)
Condido alab	99.0%	96.4%		
Candida glab- krus Contrived <sup>n</sup>	98/99	27/28	N/A	N/A
	(94.5% - 99.8%)	(82.3% - 99.4%)		
	97.3%	99.6%	97.3%	99.8%
TV	73/75 <sup>°</sup>	1332/1337 <sup>p</sup>	72/74 <sup>q</sup>	1330/1333 <sup>r</sup>
	(90.8% - 99.3%)	(99.1% - 99.8%)	(90.7% - 99.3%)	(99.3% - 99.9%)

Table 5. Performance	of the Xpert Xpress	MVP Test
----------------------	---------------------	----------

<sup>a</sup> Testing results with a second FDA-cleared NAAT: 14 were also negative and 21 were positive.

<sup>b</sup> Testing results with a second FDA-cleared NAAT: 25 were also positive and 28 were negative.

◦ Testing results with a second FDA-cleared NAAT: 12 were also negative and 22 were positive.

<sup>d</sup> Testing results with a second FDA-cleared NAAT: 23 were also positive and 38 were negative.

e Target includes C. albicans, C. tropicalis, C. parapsilosis, and C. dubliniensis

<sup>f</sup> Testing results with an FDA-cleared NAAT: 5 were also negative and 3 were positive.

g Testing results with an FDA-cleared NAAT: 31 were also positive, 24 were negative and 1 had no result.

<sup>h</sup> Testing results with an FDA-cleared NAAT: 5 were also negative and 5 were positive.

<sup>i</sup> Testing results with an FDA-cleared NAAT: 38 were also positive, 43 were negative and 1 had no result.

J Testing results with an FDA-cleared NAAT: 2 were also negative and 1 was positive.

k Testing results with an FDA-cleared NAAT: 5 were negative.

<sup>1</sup> Testing results with an FDA-cleared NAAT: 1 was also negative.

m Testing results with an FDA-cleared NAAT: 9 were negative.

<sup>n</sup> Contrived specimens were prepared using individual negative clinical CVS and SVS specimens. See Table 14 below for stratified results for Candida glabrata and Candida krusei

Testing results a second FDA-cleared NAAT: 1 was also negative and 1 was positive.

P Testing results a second FDA-cleared NAAT: 4 were also positive and 1 had no result.

q Testing results a second FDA-cleared NAAT: 1 was also negative and 1 was positive.

r Testing results a second FDA-cleared NAAT: 3 were also positive.

### **19.3 BV Performance Results**

Table 6 presents BV performance stratified by age groups in clinician-collected and self-collected swab specimens. The PPA was greater than 93.0% in all age groups except for patients aged 50 and over, in whom the PPA was 87.5% and 87.3% in CVS and SVS specimen collection types, respectively. The NPA of > 90% was observed across all age groups and specimen collection types.

Age	Clinician-col	Clinician-collected (CVS)		cted (SVS)
Group	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
	100%	100%	100%	100%
14–17	1/1	1/1	1/1	1/1
	(20.6% - 100%)	(20.6% - 100%)	(20.6% - 100%)	(20.6% - 100%)
	93.4%	92.1%	93.1%	90.7%
18–29	228/244	279/303	228/245	273/301
	(89.6% - 95.9%)	(88.5% - 94.6%)	(89.2% - 95.6%)	(86.9% - 93.5%)
	95.3%	96.3%	96.0%	93.9%
30–39	164/172	206/214	167/174	201/214
	(91.1% - 97.6%)	(92.8% - 98.1%)	(91.9% - 98.0%)	(89.9% - 96.4%)
	95.7%	91.9%	96.7%	90.4%
40–49	89/93	125/136	89/92	122/135
	(89.5% - 98.3%)	(86.1% - 95.4%)	(90.8% - 98.9%)	(84.2% - 94.3%)
	87.5%	95.2%	87.3%	96.6%
≥ 50	49/56	197/207	48/55	197/204
	(76.4% - 93.8%)	(91.3% - 97.4%)	(76.0% - 93.7%)	(93.1% - 98.3%)

#### Table 6. BV Performance by Age Group

Performance of the BV target stratified by race and ethnicity subgroups showed PPA and NPA ranging from 80.0% to 100% in most subgroups in CVS and SVS specimens (Table 7).

Baco/Ethnicity	Clinician-col	lected (CVS)	Self-collected (SVS)	
Race/Ethnicity	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
	88.9%	94.9%	90.0%	93.8%
White	193/217	554/584	198/220	546/582
	(84.1% - 92.4%)	(92.8% - 96.4%)	(85.3% - 93.3%)	(91.6% - 95.5%)
	97.2%	91.7%	96.9%	91.2%
Black or African American	316/325	220/240	313/323	218/239
	(94.8% - 98.5%)	(87.5% - 94.5%)	(94.4% - 98.3%)	(86.9% - 94.2%)
	80.0%	93.8%	80.0%	86.7%
Asian	4/5	15/16	4/5	13/15
	(37.5% - 96.4%)	(71.7% - 98.9%)	(37.5% - 96.4%)	(62.1% - 96.3%)
	83.3%	80.0%	83.3%	80.0%
American Indian or Alaska Native	5/6	4/5	5/6	4/5
	(43.6% - 97.0%)	(37.5% - 96.4%)	(43.6% - 97.0%)	(37.5% - 96.4%)

Race/Ethnicity	Clinician-collected (CVS)		Self-collected (SVS)	
Race/Ethnicity	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
	100%	0%	100%	0%
Native Hawaiian or Other Pacific Islander	2/2	0/1	2/2	0/1
	(34.2% - 100%)	(0% - 79.3%)	(34.2% - 100%)	(0% - 79.3%)
	100%	100%	100%	100%
Mixed/Unknown	11/11	15/15	11/11	13/13
	(74.1% - 100%)	(79.6% - 100%)	(74.1% - 100%)	(77.2% - 100%)
	93.9%	93.2%	95.2%	94.7%
Hispanic or Latino	77/82	123/132	79/83	124/131
	(86.5% - 97.4%)	(87.6% - 96.4%)	(88.2% - 98.1%)	(89.4% - 97.4%)

Performance of BV target in subgroups based on clinical conditions at the time of specimen collection is presented in Table 8. Results showed PPA of  $\geq$  87.5% except in subgroup of patients using estrogen therapy and NPA of  $\geq$  85.2% in all subgroups across in CVS and SVS specimen collection types.

Clinical Condition	Clinician-col	lected (CVS)	Self-colled	cted (SVS)
Clinical Condition	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
	93.3%	89.5%	95.6%	91.1%
Pregnant patients	42/45	51/57	43/45	51/56
	(82.1% - 97.7%)	(78.9% - 95.1%)	(85.2% - 98.8%)	(80.7% - 96.1%)
	97.2%	92.6%	94.1%	85.2%
Patients with menses at enrollment	35/36	50/54	32/34	46/54
	(85.8% - 99.5%)	(82.4% - 97.1%)	(80.9% - 98.4%)	(73.4% - 92.3%)
	93.3%	100%	87.5%	100%
Patients using anti-fungals ≤ 24 hours	14/15	36/36	14/16	34/34
	(70.2% - 98.8%)	(90.4% - 100%)	(64.0% - 96.5%)	(89.8% - 100%)
	100%	93.3%	100%	93.3%
Patients using antibiotics ≤ 24 hours	8/8	14/15	8/8	14/15
	(67.6% - 100%)	(70.2% - 98.8%)	(67.6% - 100%)	(70.2% - 98.8%)
	66.7%	100%	66.7%	100%
Patients using estrogen therapy ≤ 24 hours	2/3	18/18	2/3	18/18
	(20.8% - 93.8%)	(82.4% - 100%)	(20.8% - 93.8%)	(82.4% - 100%)
	95.1%	93.5%	94.8%	91.8%
Patients with recurrent symptoms	328/345	343/367	327/345	334/364
	(92.2% - 96.9%)	(90.4% - 95.6%)	(91.9% - 96.7%)	(88.5% - 94.2%)

Table 8. BV Performance by Clinical Condition

Clinical Condition	Clinician-collected (CVS)		Self-collected (SVS)	
Clinical Condition	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
Patients with intercourse ≤ 24 hours	91.4%	91.3%	91.2%	95.6%
	32/35	42/46	31/34	44/46
	(77.6% - 97.0%)	(79.7% - 96.6%)	(77.0% - 97.0%)	(85.5% - 98.8%)

### 19.4 Candida group Performance Results

As presented in Table 9, sensitivity of the Candida group target is stratified by each of the four species that are detected in the Candida group target (*C. albicans*, *C. tropicalis*, *C. parapsilosis*, and *C. dubliniensis*) as identified by the reference method.

Species	Clinician-collected (CVS)	Self-collected (SVS)
Species	Sensitivity	y (95% CI)
	98.4%	97.9%
Candida albicans	371/377	368/376
	(96.6% - 99.3%)	(95.9% - 98.9%)
Co-infection Candida albicans	100%	100%
	6/6	6/6
and Candida glabrata	(61.0% - 100%)	(61.0% - 100%)
Co. infontion. Condido alkiana	100%	100%
Co-infection <i>Candida albicans</i>	1/1	1/1
and Candida krusei	(20.6% - 100%)	(20.6% - 100%)
	100%	100.0%
Co-infection <i>Candida albicans</i>	1/1	1/1
and Candida parapsilosis	(20.6% - 100%)	(20.6% - 100%)
Co-infection Candida albicans	80.0%	60.0%
	4/5	3/5
and other yeast	(37.5% - 96.4%)	(23.1% - 88.2%)
	100%	100%
Candida dubliniensis	5/5	5/5
	(56.5% - 100%)	(56.5% - 100%)
	80.0%	100.0%
Candida parapsilosis	4/5	5/5
	(37.5% - 96.4%)	(56.5% - 100%)
	100%	100%
Candida tropicalis	4/4	4/4
	(51.0% - 100%)	(51.0% - 100%)

#### Table 9. Candida group Sensitivity by Species

Species	Clinician-collected (CVS)	Self-collected (SVS)	
opecies	Sensitivity (95% CI)		
	98.0%	97.5%	
Overall	396/404	393/403	
	(96.1% - 99.0%)	(95.5% - 98.7%)	

As presented in Table 10, performance of the Candida group target stratified by age groups showed sensitivity and specificity of 91.5% or higher across all age groups and specimen collection types.

Age	Clinician-col	lected (CVS)	Self-colled	cted (SVS)
Group	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
	100%		100%	
14–17	2/2	N/A	2/2	N/A
	(34.2% - 100%)		(34.2% - 100%)	
	98.2%	93.9%	97.4%	91.5%
18–29	225/229	308/328	222/228	300/328
	(95.6% - 99.3%)	(90.8% - 96.0%)	(94.4% - 98.8%)	(87.9% - 94.0%)
	99.0%	93.8%	96.0%	91.8%
30–39	100/101	273/291	97/101	269/293
	(94.6% - 99.8%)	(90.4% - 96.0%)	(90.3% - 98.4%)	(88.1% - 94.4%)
	97.9%	94.5%	100%	91.7%
40–49	47/48	172/182	48/48	165/180
	(89.1% - 99.6%)	(90.2% - 97.0%)	(92.6% - 100%)	(86.7% - 94.9%)
	91.7%	96.6%	100%	93.6%
≥ 50	22/24	231/239	24/24	220/235
	(74.2% - 97.7%)	(93.5% - 98.3%)	(86.2% - 100%)	(89.7% - 96.1%)

#### Table 10. Candida group Performance by Age Group

Performance of the Candida group target stratified by race and ethnicity subgroups showed sensitivity of > 97.0% and specificity of > 88.0% in all subgroups except in Asian patients in CVS and SVS specimen collection types (Table 11).

	Clinician-col	llected (CVS)	Self-collee	cted (SVS)
Race/Ethnicity	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)
	97.2%	95.6%	98.2%	92.8%
White	209/215	570/596	212/216	553/596
	(94.0% - 98.7%)	(93.7% - 97.0%)	(95.3% - 99.3%)	(90.4% - 94.6%)
	98.8%	93.2%	97.1%	91.1%
Black or African American	170/172	370/397	167/172	359/394
	(95.9% - 99.7%)	(90.3% - 95.3%)	(93.4% - 98.8%)	(87.9% - 93.5%)
	100%	88.2%	80.0%	87.5%
Asian	5/5	15/17	4/5	14/16
	(56.5% - 100%)	(65.7% - 96.7%)	(37.5% - 96.4%)	(64.0% - 96.5%)
	100%	88.9%	100%	88.9%
American Indian or Alaska Native	2/2	8/9	2/2	8/9
	(34.2% - 100%)	(56.5% - 98.0%)	(34.2% - 100%)	(56.5% - 98.0%)
		100%		100%
Native Hawaiian or Other Pacific Islander	N/A	3/3	N/A	3/3
		(43.9% - 100%)		(43.9% - 100%)
	100%	100%	100%	94.4%
Mixed/Unknown	10/10	18/18	8/8	17/18
	(72.2% - 100%)	(82.4% - 100%)	(67.6% - 100%)	(74.2% - 99.0%)
	98.5%	96.1%	98.5%	92.8%
Hispanic or Latino	66/67	146/152	65/66	142/153
	(92.0% - 99.7%)	(91.7% - 98.2%)	(91.9% - 99.7%)	(87.6% - 95.9%)

 Table 11. Candida group Performance by Race and Ethnicity

Performance of the Candida group target in subgroups based on clinical conditions at the time of specimen collection is presented in Table 12. Results showed sensitivity and specificity ranging from 82.1% to 100% in CVS and SVS specimen collection types.

	Clinician-col	lected (CVS)	Self-colled	cted (SVS)
Clinical Condition	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% Cl)
	98.0%	92.5%	95.9%	94.3%
Pregnant patients	49/50	49/53	47/49	50/53
	(89.5% - 99.7%)	(82.1% - 97.0%)	(86.3% - 98.9%)	(84.6% - 98.1%)
	100%	97.2%	100%	92.9%
Patients with menses at enrollment	20/20	70/72	20/20	65/70
	(83.9% - 100%)	(90.4% - 99.2%)	(83.9% - 100%)	(84.3% - 96.9%)
	100%	82.1%	95.5%	82.1%
Patients using anti-fungals ≤ 24 hours	23/23	23/28	21/22	23/28
	(85.7% - 100%)	(64.4% - 92.1%)	(78.2% - 99.2%)	(64.4% - 92.1%)
	100%	86.7%	100%	86.7%
Patients using antibiotics ≤ 24 hours	9/9	13/15	9/9	13/15
	(70.1% - 100%)	(62.1% - 96.3%)	(70.1% - 100%)	(62.1% - 96.3%)
	83.3%	100%	100%	100%
Patients using estrogen therapy ≤ 24 hours	5/6	15/15	6/6	15/15
	(43.6% - 97.0%)	(79.6% - 100%)	(61.0% - 100%)	(79.6% - 100%)
Patient with recurrent	98.1%	96.1%	97.2%	92.0%
symptoms	210/214	491/511	205/211	470/511
	(95.3% - 99.3%)	(94.0% - 97.4%)	(93.9% - 98.7%)	(89.3% - 94.0%)
	100%	96.6%	100%	94.7%
Patient with intercourse ≤ 24 hours	24/24	57/59	25/25	54/57
	(86.2% - 100%)	(88.5% - 99.1%)	(86.7% - 100%)	(85.6% - 98.2%)

### 19.5 Candida glab-krus Performance Results

Performance of the Candida glab-krus target was evaluated in fresh and contrived specimens. Table 13 presents sensitivity of the Candida glab-krus target from fresh perspective specimens stratified by *C. glabrata* and C. *krusei*.

Species	Clinician-collected (CVS)	Self-collected (SVS)		
Species	Sensitivity (95% CI)			
	95.5%	97.7%		
Candida glabrata	42/44	42/43		
	(84.9% - 98.7%)	(87.9% - 99.6%)		
	66.7%	100%		
Candida krusei	2/3	3/3		
	(20.8% - 93.8%)	(43.9% - 100%)		
	93.6%	97.8%		
Overall	44/47 <sup>a</sup>	45/46 <sup>b</sup>		
	(82.8% - 97.8%)	(88.7% - 99.6%)		

Table 13.	Candida d	lab-krus	Sensitivity	in Fresh	Specimens	by Species

a Testing results with an FDA-cleared NAAT: 2 were also positive and 1 was negative.

 $^{\rm b}\,$  Testing results with an FDA-cleared NAAT: 1 was negative.

Table 14 presents a summary of performance of the Candida glab-krus target in contrived specimens, including the concentrations that were tested as well as the number of replicates tested at each concentration.

Contrived Specimen	Load (× LoD)	Concentration (CFU/mL)	N of Replicates	Evaluable Results N = 127	
-			Tested	PPA (95% CI)	NPA (95% CI)
	Low (1.8×) Candida glabrata (9.5×)	36	25	96.0% 24/25 <sup>a</sup> (80.5% - 99.3%)	N/A
		190	20	100% 20/20 (83.9% - 100%)	N/A
	High (19×)	380	5	100% 5/5 (56.5% - 100%)	N/A
Candida krusei	Low (1.8×)	1,181	25	100.0% 25/25 (86.7% - 100.0%)	N/A

Contrived Specimen	Replicates		Replicates	Evaluable Results N = 127	
		Tested	PPA (95% CI)	NPA (95% CI)	
	Moderate (8.5×)	5,576	20	100.0% 20/20 (83.9% - 100%)	N/A
	High (19×)	12,464	5 <sup>b</sup>	100% 4/4 (51.0% - 100%)	N/A
Negative	N/A	N/A	30 <sup>c</sup>	N/A	96.4% 27/28 <sup>d</sup> (82.3% - 99.4%)
Total		130 <sup>e</sup>	99.0% 98/99 (89.5% - 99.6%)	96.4% 27/28 (82.3% - 99.4%)	

<sup>a</sup> One false negative was a low positive specimen prepared at 1.8× LoD.

b A total of five specimens were tested. Four specimens gave valid results and were included in the calculation. One specimen was not included in the calculation due to a final non-determinate result.

c A total of 30 specimens were tested. 28 specimens gave valid results and were included in the calculation. Two specimens were not included in the calculation due to a final non-determinate result.

 $\ensuremath{^{\text{d}}}$  One false positive was detected at a Ct value of 39.3.

e Of the 130 tested contrived specimens, three gave initial non-determinate results. Two of the three (2/3) specimens were retested and generated final non-determinate results. One of the three (1/3) specimens was not retested. Both the initial and final non-determinate rates were 2.3% (3/130).

As presented in Table 15, performance of the Candida glab-krus target stratified by age groups showed sensitivity of 81.8% or higher and specificity of 98.6% or higher across all age groups and specimen collection types.

Age	Clinician-col	lected (CVS)	Self-collected (SVS)		
Group	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	
		100%		100%	
14–17	N/A	2/2	N/A	2/2	
		(34.2% - 100%)		(34.2% - 100%)	
	81.8%	99.6%	100%	100%	
18–29	9/11	544/546	10/10	546/546	
	(52.3% - 94.9%)	(98.7% - 99.9%)	(72.2% - 100%)	(99.3% - 100%)	
	90.9%	100%	90.9%	99.0%	
30–39	10/11	381/381	10/11	379/383	
	(62.3% - 98.4%)	(99.0% - 100%)	(62.3% - 98.4%)	(97.4% - 99.6%)	

Age	Clinician-col	llected (CVS)	Self-collected (SVS)		
Group	Sensitivity (95% CI) Specificity (95% CI)		Sensitivity (95% CI)	Specificity (95% CI)	
	100%	99.6%	100%	98.6%	
40–49 9/9	9/9	220/221	9/9	216/219	
	(70.1% - 100%)	(97.5% - 99.9%)	(70.1% - 100%)	(96.0% - 99.5%)	
	100%	99.2%	100%	99.2%	
≥ 50	16/16	245/247	16/16	241/243	
	(80.6% - 100%)	(97.1% - 99.8%)	(80.6% - 100%)	(97.0% - 99.8%)	

Performance of the Candida glab-krus target stratified by race and ethnicity subgroups showed sensitivity ranging from 91.7% to 100% and specificity ranging from 99.2% to 100% in CVS and SVS specimen collection types (Table 16).

Table 16. Candida glab-krus Performance by Race and Ethnicity

	Clinician-col	lected (CVS)	Self-collected (SVS)		
Race/Ethnicity	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	
	91.7%	99.6%	100%	99.2%	
White	22/24	784/787	24/24	782/788	
	(74.2% - 97.7%)	(98.9% - 99.9%)	(86.2% - 100%)	(98.4% - 99.7%)	
	95.5%	99.6%	95.2%	99.5%	
Black or African American	21/22	545/547	20/21	542/545	
	(78.2% - 99.2%)	(98.7% - 99.9%)	(77.3% - 99.2%)	(98.4% - 99.8%)	
		100%		100%	
Asian	N/A	22/22	N/A	21/21	
		(85.1% - 100%)		(84.5% - 100%)	
		100%		100%	
American Indian or Alaska Native	N/A	11/11	N/A	11/11	
		(74.1% - 100%)		(74.1% - 100%)	
		100%		100%	
Native Hawaiian or Other Pacific Islander	N/A	3/3	N/A	3/3	
		(43.9% - 100%)		(43.9% - 100%)	
	100%	100%	100%	100%	
Mixed/Unknown	1/1	27/27	1/1	25/25	
	(20.6% - 100%)	(87.5% - 100%)	(20.6% - 100%)	(86.7% - 100%)	
	100%	100%	100%	100%	
Hispanic or Latino	7/7	212/212	7/7	212/212	
	(64.6% - 100%)	(98.2% - 100%)	(64.6% - 100%)	(98.2% - 100%)	

Performance of the Candida glab-krus target in subgroups based on clinical conditions at the time of specimen collection is presented in Table 17. Results showed sensitivity and specificity ranging from 75.0% to 100% in CVS and SVS specimen collection types.

	Clinician-col	llected (CVS)	Self-collected (SVS)		
Clinical Condition	Sensitivity (95% CI)	Specificity (95% CI)	Sensitivity (95% CI)	Specificity (95% CI)	
	100%	100%	100%	99.0%	
Pregnant patients	1/1	102/102	1/1	100/101	
	(20.6% - 100%)	(96.4% - 100%)	(20.6% - 100%)	(94.6% - 99.8%)	
	80.0%	100%	75.0%	100%	
Patients with menses at enrollment	4/5	87/87	3/4	86/86	
	(37.5% - 96.4%)	(95.8% - 100%)	(30.1% - 95.4%)	(95.7% - 100%)	
		100%		100%	
Patients using anti-fungals ≤ 24 hours	N/A	51/51	N/A	50/50	
		(93.0% - 100% )		(92.9% - 100%)	
	100%	100%	100%	100%	
Patients using antibiotics ≤ 24 hours	1/1	23/23	1/1	23/23	
	(20.6% - 100%)	(85.7% - 100%)	(20.6% - 100%)	(85.7% - 100%)	
		100%		100%	
Patients using estrogen therapy ≤ 24 hours	N/A	21/21	N/A	21/21	
		(84.5% - 100%)		(84.5% - 100%)	
	100%	99.4%	100%	99.1%	
Patient with recurrent symptoms	24/24	697/701	23/23	693/699	
	(86.2% - 100%)	(98.5% - 99.8%)	(85.7% - 100%)	(98.1% - 99.6%)	
	100%	97.5%	100%	98.8%	
Patient with intercourse ≤ 24 hours	2/2	79/81	2/2	79/80	
	(34.2% - 100%)	(91.4% - 99.3%)	(34.2% - 100%)	(93.2% - 99.8%)	

Table 17.	Candida	glab-krus	Performance	by Clinical	Condition
10010 17.	ounaidu	gius muo	1 offormation	sy ennour	oonantion

### **19.6 TV Performance Results**

As presented in Table 18, performance of the TV target stratified by age groups showed PPA and NPA of 93.8% or higher across all age groups and specimen collection types.

Age	Clinician-col	lected (CVS)	Self-collected (SVS)			
Group	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)		
		100%		100%		
14–17	N/A	2/2	N/A	2/2		
		(34.2% - 100%)		(34.2% - 100%)		
	96.2%	99.8%	96.2%	100%		
18–29	25/26	512/513	25/26	512/512		
	(81.1% - 99.3%)	(98.9% - 100%)	(81.1% - 99.3%)	(99.3% - 100%)		
	100%	99.4%	100%	99.4%		
30–39	26/26	353/355	26/26	355/357		
	(87.1% - 100%)	(98.0% - 99.9%)	(87.1% - 100%)	(98.0% - 99.9%)		
	94.1% 99.5%		93.8%	100%		
40–49	16/17	211/212	15/16	211/211		
	(73.0% - 99.0%)	(97.4% - 99.9%)	(71.7% - 98.9%)	(98.2% - 100%)		
	100%	99.6%	100%	99.6%		
≥ 50	6/6	254/255	6/6	250/251		
	(61.0% - 100%)	(97.8% - 99.9%)	(61.0% - 100%)	(97.8% - 99.9%)		

Table 18. TV Performance by Age Group

Performance of the TV target stratified by race and ethnicity subgroups showed PPA ranging from 83.3% to 100% and NPA ranging from 99.2% to 100% in CVS and SVS specimen collection types (Table 19).

Decc/Ethnicity	Clinician-col	lected (CVS)	Self-colled	cted (SVS)
Race/Ethnicity	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)
	93.3%	99.9%	93.3%	100%
White	14/15	775/776	14/15	777/777
	(70.2% - 98.8%)	(99.3% - 100%)	(70.2% - 98.8%)	(99.5% - 100%)
	98.3%	99.2%	98.3%	99.4%
Black or African American	58/59	497/501	57/58	496/499
	(91.0% - 99.7%)	(98.0% - 99.7%)	(90.9% - 99.7%)	(98.2% - 99.8%)
		100%		100%
Asian	N/A	21/21	N/A	20/20
		(84.5% - 100%)		(83.9% - 100%)
	100%	100%	100%	100%
American Indian or Alaska Native	1/1	10/10	1/1	10/10
	(20.6% - 100%)	(72.2% - 100%)	(20.6% - 100%)	(72.2% - 100%)
		100%		100%
Native Hawaiian or Other Pacific Islander	N/A	3/3	N/A	3/3
		(43.9% - 100%)		(43.9% - 100%)
		100%		100%
Mixed/Unknown	N/A	26/26	N/A	24/24
		(87.1% - 100%)		(86.2% - 100%)
	83.3%	100%	83.3%	100%
Hispanic or Latino	5/6	205/205	5/6	205/205
	(43.6% - 97.0%)	(98.2% - 100%)	(43.6% - 97.0%)	(98.2% - 100%)

Table 19. TV Performance by Race and Ethnicity

Performance of the TV target in subgroups based on clinical conditions at the time of specimen collection is presented in Table 20. Results showed PPA ranging from 85.7% to 100% and NPA ranging from 97.9% to 100% in most subgroups in CVS and SVS specimen collection types.

Clinical Condition	Clinician-col	llected (CVS)	Self-collected (SVS)			
Clinical Condition	PPA (95% CI)	NPA (95% CI)	PPA (95% CI)	NPA (95% CI)		
	100%	100%	100%	100%		
Pregnant patients	3/3	94/94	3/3	93/93		
	(43.9% - 100%)	(96.1% - 100%)	(43.9% - 100%)	(96.0% - 100%)		
	85.7%	100%	85.7%	100%		
Patients with menses at enrollment	6/7	81/81	6/7	79/79		
	(48.7% - 97.4%)	(95.5% - 100%)	(48.7% - 97.4%)	(95.4% - 100%)		
	100%	98.0%	100%	97.9%		
Patients using anti-fungals ≤ 24 hours	2/2	48/49	2/2	47/48		
	(34.2% - 100%)	(89.3% - 99.6%)	(34.2% - 100%)	(89.1% - 99.6%)		
	0%	100%	0%	100%		
Patients using antibiotics ≤ 24 hours	0/1	22/22	0/1	22/22		
	(0% - 79.3%)	(85.1% - 100%)	(0% - 79.3%)	(85.1% - 100%)		
		100%		100%		
Patients using estrogen therapy ≤ 24 hours	N/A	21/21	N/A	21/21		
		(84.5% - 100%)		(84.5% - 100%)		
	97.8%	99.4%	97.8%	99.5%		
Patient with recurrent symptoms	45/46	653/657	44/45	652/655		
	(88.7% - 99.6%)	(98.4% - 99.8%)	(88.4% - 99.6%)	(98.7% - 99.8%)		
	100%	100%	100%	100%		
Patient with intercourse ≤ 24 hours	5/5	76/76	5/5	75/75		
	(56.5% - 100%)	(95.2% - 100%)	(56.5% - 100%)	(95.1% - 100%)		

### 19.7 Multi-Target Detection

Rates of multi-target detection for the Xpert Xpress MVP test are presented in Table 21, which includes specimens with valid results in all four targets of the Xpert Xpress MVP test and by the reference/comparator method (1,433 of 1,473 total CVS specimens, and 1,428 of 1,474 total SVS specimens). Overall, 17.4% of CVS specimens and 18.4% SVS specimens resulted in positive results for more than one target in the Xpert Xpress MVP test. The most prevalent multi-target detection in both CVS and SVS specimens was a combination of BV and Candida group (11.2% and 11.8%, respectively), followed by a combination of BV and 3.6%, respectively).

Analytes Detected	Clinician-collected (CVS)	Self-collected (SVS)
BV,	11.2%	11.8%
Candida group	161/1433	169/1428
BV,	3.6%	3.6%
TV	52/1433	52/1428
BV, Candida group, TV	0.9% 13/1433	0.8% 12/1428
BV, Candida glab-krus	0.5% 7/1433	0.5% 7/1428
Candida group, Candida glab-krus	0.3% 5/1433	0.6% 8/1428
BV, Candida group <i>,</i> Candida glab-krus	0.3% 5/1433	0.7% 10/1428
Candida group, TV	0.3% 4/1433	0.3% 4/1428
Candida glab-krus, TV	0.1% 1/1433	0.1% 1/1428
Candida group, Candida glab-krus, TV	0.1% 1/1433	N/A
Total	17.4% 249/1433	18.4% 263/1428

The number of fresh specimens with positive results for more than one target as determined by the Xpert Xpress MVP test or reference/comparator methods are summarized in Table 22, where bolded values indicate concordant results and non-bolded values indicate discordant results.

Among 1,433 CVS specimens, 191 specimens yielded multi-target concordant results between Xpert Xpress MVP and reference methods. Of the 191 specimens, 66.0% (126/191) had concordant BV and Candida group co-infections, and 23.6% (45/191) had concordant BV and TV co-infections. Among 1,428 SVS specimens, 183 specimens yielded multi-target concordant results. Of the 183 specimens, 65.0% (119/183) had concordant BV and Candida group co-infections, and 24.0% (44/183) had concordant BV and TV co-infections.

	Total Number of Occurrences between the Xpert Xpress MVP Test vs. Reference/Comparator Method (CVS/SVS)													
	Infections	BV	BV, Candida group	BV, Candida glab-krus	BV, Candida group, Candida glab-krus	BV, TV	BV, Candida group, TV	Candida group	Candida group, Candida glab-krus	Candida group, TV	Candida glab-krus	Candida glab-krus, TV	Λ1	Negative
	BV		0/5	-	-	-	-	1/0	-	-	-	-	-	26/28
	BV, Candida group	16/26	126/119	-	1/0	-	-	16/22	1/0	-	-	-	-	1/2
	BV, Candida glab- krus	2/3	-	3/1	-	-	-	-	-	-	2/3	-	-	-
NVP Test	BV, Candida group, Candida glab- krus	0/1	-	0/2	4/5	-	-	-	0/1	-	1/1	-	-	-
The Xpert Xpress MVP Test	BV, TV	2/2	-	-	-	45/44	1/1	-	-	-	-	-	4/5	-
The Xpe	BV, Candida group, TV	-	-	-	-	3/3	9/9	-	-	1/0	-	-	-	-
	Candida group	1/2	14/15	-	-	-	-		-	1/1	1/1	-	-	27/36
	Candida group, Candida glab- krus	-	-	1/1	-	-	-	-	1/1	-	3/6	-	-	-
	Candida group, TV	-	-	-	-	-	-	1/0	-	2/3	-	-	-	1/1

#### Table 22. Multi-Target Detection by the Xpert Xpress MVP Test

Total Number of Occurrences between the Xpert Xpress MVP Test vs. Reference/Comparator Method (CVS/SVS)													
Infections	BV	BV, Candida group	BV, Candida glab-krus	BV, Candida group, Candida glab-krus	BV, TV	BV, Candida group, TV	Candida group	Candida group, Candida glab-krus	Candida group, TV	Candida glab-krus	Candida glab-krus, TV	λL	Negative
Candida group, Candida glab- krus, TV	-	_	-	_	-	_	-	-	-	1/0	-	-	-
Candida glab- krus	-	-	1/0	-	-	-	-	-	-		-	-	3/5
Candida glab- krus, TV	-	-	-	-	-	-	-	-	-	-	1/1	-	-
ΤV	-	-	-	-	1/1	-	-	-	-	-	-		-
Negative	17/15	-	-	-	-	-	6/4	-	-	-	-	1/1	

### 19.8 Non-Determinate Rate

Of the 2,947 Xpert Xpress MVP runs performed in the clinical study, 130 resulted in non-determinate (**Error**, **Invalid** or **No Results**) results on first attempt. Upon retest of these 130 specimens, 22 remained non-determinate. The initial non-determinate rate was 4.4% (130/2947) and the overall non-determinate rate was 0.7% (22/2947).

The initial non-determinate rate for CVS specimens was 3.9% (58/1473) and the overall non-determinate rate was 0.5% (8/1473). The initial non-determinate rate for SVS specimens was 4.9% (72/1474) and the overall non-determinate rate was 0.9% (14/1474).

# 20 Analytical Performance

### 20.1 Analytical Sensitivity (Limit of Detection)

The analytical sensitivity of the Xpert Xpress MVP test was determined by preparing dilutions for each of the target organisms detected by the test. The near cut-off concentrations for the BV organisms were also determined. Positive samples were prepared by inoculating simulated vaginal swab matrix with each representative strain or quantified stocks of plasmid DNA containing the cloned genomic targets of BVAB2 or *Megasphaera*-1. Replicates of 20 were evaluated at a minimum of five concentrations for each of the target organisms. The limit of detection (LoD) and near cut-off concentrations for the target organisms were estimated by probit analysis. The LoD is defined as the lowest concentration of organism sample that can be reproducibly distinguished from negative samples with 95% confidence. The near cut-off concentration for the BV organisms is defined as the lowest concentrations of *Atopobium vaginae* and *Megasphaera*-1, or *A. vaginae* and BVAB2, or *A. vaginae* in the absence of *Megasphaera*-1 and BVAB2 that result in

BV POSITIVE test results and can be reproducibly distinguished from negative samples with a 95% confidence level. The LoD for each *Candida* spp. and *Trichomonas vaginalis* strain was confirmed in natural clinical vaginal swab matrix and simulated vaginal swab matrix (Table 23). The LoD and near cut-off concentrations for each BV organism were confirmed in simulated vaginal swab matrix (Table 23 and Table 24).

Target	Strain	LoD	Units
	Atopobium vaginae ATCC BAA-55	32	CFU/mL
BV	Megasphaera-1 plasmid DNA	338	copies/mL
	BVAB2 plasmid DNA	50	copies/mL
	Candida albicans ATCC 32032	30	CFU/mL
Candida group	Candida dubliniensis ATCC 44508	1,316	CFU/mL
	Candida tropicalis ATCC 13803	750	CFU/mL
	Candida parapsilosis ATCC 22019	1,339	CFU/mL
Candida glab-krus	Candida glabrata ATCC 28482	20	CFU/mL
	Candida krusei ATCC 34135	656	CFU/mL
TV	Trichomonas vaginalis ATCC 30001	5	cells/mL

#### Table 23. Limit of Detection of BV, Candida group, Candida glab-krus, and TV Targets for Xpert Xpress MVP

#### Table 24. Near Cut-off Concentration of BV Target for Xpert Xpress MVP

Target	Strain	Near Cut-off concentration	Units
	<i>Atopobium vaginae</i> ATCC BAA-55 (in the absence of <i>Megasphaera</i> -1 and BVAB2)	320,000	CFU/mL
BV	<i>Atopobium vaginae</i> ATCC BAA-55 (in the presence of <i>Megasphaera</i> -1 and BVAB2)	2,750	CFU/mL
	Megasphaera-1 plasmid DNA	390	copies/mL
	BVAB2 plasmid DNA	50	copies/mL

### 20.2 Analytical Reactivity (Inclusivity)

The analytical reactivity (inclusivity) of the Xpert Xpress MVP test was determined with 5 strains of *Candida albicans*, 5 strains of *C. dubliniensis*, 5 strains of *C. tropicalis*, 5 strains of *C. parapsilosis*, 5 strains of *C. glabrata*, 5 strains of *C. krusei*, 11 strains of *Atopobium* spp. (*Atopobium vaginae* and/or *Atopobium* novel species CCUG 55226), and 10 strains of *Trichomonas vaginalis* that were diluted in simulated vaginal swab matrix at 3× LoD. Each *Atopobium* spp. strain was also evaluated at 3× near cut-off concentrations diluted in simulated vaginal swab matrix in the absence or presence of BVAB2 and/or *Megasphaera*-1 DNA to confirm the correct **BV POSITIVE** test results were reported. Three replicates were tested for each strain.

The Xpert Xpress MVP test correctly identified 46 of 51 strains upon initial testing at  $3 \times \text{LoD}$ . Two strains of *Atopobium vaginae* tested at  $3 \times \text{LoD}$  and three strains of *Candida albicans* tested at  $3 \times \text{LoD}$  were not detected and were tested at higher concentrations to determine the minimum concentration sufficient for detection. One *A. vaginae* strain was detected at  $\sim 4 \times \text{LoD}$  and the other strain was detected at  $\sim 12 \times \text{LoD}$ . One *C. albicans* strain was detected at  $\sim 4 \times \text{LoD}$  and the other two *C. albicans* strains were detected at  $\sim 20 \times \text{LoD}$ . For near cut-off concentration of *Atopobium* spp. in the absence of *Megasphaera*-1 and BVAB2, the Xpert Xpress MVP test correctly reported **BV POSITIVE** test result for 7 of the 11 strains upon initial testing at  $3 \times \text{near cut-off}$  concentration. Four strains did not meet acceptance criteria and were further tested

to determine the minimum concentration sufficient for reporting **BV POSITIVE** test result. One *Atopobium* spp. strain reported **BV POSITIVE** at ~4×, two strains at ~6×, and one strain at ~12× near cut-off concentration. For the near cut-off concentration of *Atopobium* spp. in the presence of *Megasphaera*-1 and/or BVAB2, the Xpert Xpress MVP test correctly reported **BV POSITIVE** test result for 7 of the 11 strains upon initial testing at 3× near cut-off concentration. Four strains did not meet acceptance criteria and were further tested to determine the minimum concentration sufficient for reporting **BV POSITIVE** test result. Two *Atopobium* spp. strains reported **BV POSITIVE** at ~4×, one strain at ~6×, and one strain at ~7× near cut-off concentration. The inclusivity result summary is presented in Table 25.

			Result					
Organism	Strain	Concentration	BV	Candida group	Candida glab-krus	тv		
	Negative Control		Negative	Not Detected	Not Detected	Not Detected		
	CCUG 39382	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
	CCUG 42099	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
Atopobium	CCUG 43049	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
spp.	CCUG 44061	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
LoD (Rolow the	CCUG 44116	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
(Below the near cut-off	CCUG 44125	120 CFU/mL <sup>b</sup>	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
concentrations and not	CCUG 44156	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
generating BV POSITIVE	CCUG 44258	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
result) <sup>a</sup>	CCUG 48515	400 CFU/mL <sup>c</sup>	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
	CCUG 55227	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
	CCUG 55226	96 CFU/mL	pos <sup>a</sup>	Not Detected	Not Detected	Not Detected		
	CCUG 39382	9.6×10⁵ CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 42099	9.6×10⁵ CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 43049	9.6×10⁵ CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
Atopobium	CCUG 44061	9.6×10⁵ CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
spp. In the <b>absence</b> of	CCUG 44116	9.6×10⁵ CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
Megasphaera-1 and BVAB2	CCUG 44125	1.2×10 <sup>6</sup> CFU/mL <sup>d</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44156	2.0×10 <sup>6</sup> CFU/mL <sup>e</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44258	9.6×10 <sup>5</sup> CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 48515	4.0×10 <sup>6</sup> CFU/mL <sup>f</sup>	Positive	Not Detected	Not Detected	Not Detected		

Table 25. Analytical Reactivity (Inclusivity) of the Xpert Xpress MVP test

			Result					
Organism	Strain	Concentration	BV	Candida group	Candida glab-krus	тv		
	CCUG 55227	9.6×10 <sup>5</sup> CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 55226	2.0×10 <sup>6</sup> CFU/mL <sup>g</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 39382	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 42099	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 43049	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44061	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44116	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
<i>Atopobium</i> spp.	CCUG 44125	10,000 CFU/mL <sup>h</sup>	Positive	Not Detected	Not Detected	Not Detected		
In the <b>presence</b>	CCUG 44156	17,000 CFU/mL <sup>i</sup>	Positive	Positive Not Detected Not Dete		Not Detected		
of BVAB2	CCUG 44258	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 48515	17,000 CFU/mL <sup>j</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 55227	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 55226	10,000 CFU/mL <sup>k</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 39382	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 42099	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 43049	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44061	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 44116	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
Atopobium spp.	CCUG 44125	10,000 CFU/mL <sup>h</sup>	Positive	Not Detected	Not Detected	Not Detected		
In the presence of	CCUG 44156	17,000 CFU/mL <sup>i</sup>	Positive	Not Detected	Not Detected	Not Detected		
Megasphaera-1	CCUG 44258	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 48515	20,000 CFU/mL <sup>j</sup>	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 55227	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected		
	CCUG 55226	10,000 CFU/mL <sup>k</sup>	Positive	Not Detected	Not Detected	Not Detected		

			Result			
Organism	Strain	Concentration	BV	Candida group	Candida glab-krus	тv
	CCUG 39382	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 42099	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 43049	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 44061	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 44116	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
Atopobium spp.	CCUG 44125	10,000 CFU/mL <sup>h</sup>	Positive	Not Detected	Not Detected	Not Detected
In the <b>presence</b> of <i>Megasphaera</i> -1	CCUG 44156	17,000 CFU/mL <sup>i</sup>	Positive	Not Detected	Not Detected	Not Detected
and BVAB2	CCUG 44258	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 48515	17,000 CFU/mL <sup>j</sup>	Positive	Not Detected	Not Detected	Not Detected
	CCUG 55227	8,250 CFU/mL	Positive	Not Detected	Not Detected	Not Detected
	CCUG 55226	10,000 CFU/mL <sup>k</sup>	Positive	Not Detected	Not Detected	Not Detected
Candida	ATCC 38289	120 CFU/mL <sup>I</sup>	Negative	Detected	Not Detected	Not Detected
	ATCC 62376	600 CFU/mL <sup>m</sup>	Negative	Detected	Not Detected	Not Detected
Candida albicans	ATCC 96113	90 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC 60193	90 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC 753	600 CFU/mL <sup>n</sup>	Negative	Detected	Not Detected	Not Detected
	ATCC MYA-179	3,948 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC MYA-577	3,948 CFU/mL	Negative	Detected	Not Detected	Not Detected
Candida dubliniensis	ATCC MYA-646	3,948 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC MYA-580	3,948 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC MYA-581	3,948 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC 34139	2,250 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC 90874	2,250 CFU/mL	Negative	Detected	Not Detected	Not Detected
Candida	ATCC 204318	2,250 CFU/mL	Negative	Detected	Not Detected	Not Detected
tropicalis	ATCC MYA-2733	2,250 CFU/mL	Negative	Detected	Not Detected	Not Detected
	ATCC MYA-277	2,250 CFU/mL	Negative	Detected	Not Detected	Not Detected

				Result			
Organism	Strain	Concentration	BV	Candida group	Candida glab-krus	тv	
	ATCC 7330	4,017 CFU/mL	Negative	Detected	Not Detected	Not Detected	
	ATCC 60548	4,017 CFU/mL	Negative	Detected	Not Detected	Not Detected	
Candida parapsilosis	ATCC 90875	4,017 CFU/mL	Negative	Detected	Not Detected	Not Detected	
, ,	ATCC 96139	4,017 CFU/mL	Negative	Detected	Not Detected	Not Detected	
	ATCC 96140	4,017 CFU/mL	Negative	Detected	Not Detected	Not Detected	
	ATCC 32312	60 CFU/mL	Negative	Not Detected	Detected	Not Detected	
	ATCC 32554	60 CFU/mL	Negative	Not Detected	Detected	Not Detected	
Candida	ATCC 15126	60 CFU/mL	Negative	Not Detected	Detected	Not Detected	
glabrata	ATCC 2001	60 CFU/mL	Negative	Not Detected	Detected	Not Detected	
ATCC MYA-276 60 CFU/mL	Negative	Not Detected	Detected	Not Detected			
	ATCC 28870	1,968 CFU/mL	Negative	Not Detected	Detected	Not Detected	
	ATCC 32672	1,968 CFU/mL	Negative	Not Detected	Detected	Not Detected	
Candida krusei	ATCC 90878	1,968 CFU/mL	Negative	Not Detected	Detected	Not Detected	
	ATCC 200917	1,968 CFU/mL	Negative	Not Detected	Detected	Not Detected	
	ATCC 201748	1,968 CFU/mL	Negative	Not Detected	Detected	Not Detected	
	ATCC 30184	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 30187	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 30238°	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 30240	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
Trichomonas	ATCC 30245	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
vaginalis	ATCC 50139	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 50141	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 50167	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC 50183	15 cells/mL	Negative	Not Detected	Not Detected	Detected	
	ATCC PRA-95	15 cells/mL	Negative	Not Detected	Not Detected	Detected	

<sup>a</sup> The LoD for *Atopobium vaginae* is for information only. All *Atopobium* spp. strains tested at ~3× LoD level reported BV NEGATIVE result calls as expected, as the concentration of *Atopobium* spp. strains tested was below the near cut-off concentration either in the presence or absence of Mega1-BVAB2 target. Replicates reporting Atop gp Ct values of ≤ 40.0 was treated as positive (pos) when *Atopobium* spp. strains were tested at ~ 3× LoD.

b Atopobium vaginae CCUG 44125 was tested at ~ 4× LoD (120 CFU/mL) to obtain 3 of 3 Atop gp Ct values of ≤ 40.0 results.

c Atopobium vaginae CCUG 48515 was tested at ~ 12× LoD (400 CFU/mL) to obtain 3 of 3 Atop gp Ct values of ≤ 40.0 results.

<sup>d</sup> Atopobium vaginae CCUG 44125 was tested at ~ 4× near cut-off concentration (1.2×10<sup>6</sup> CFU/mL) in the absence of BVAB2 and Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.

 Atopobium vaginae CCUG 44156 was tested at ~ 6× near cut-off concentration (2.0×10<sup>6</sup> CFU/mL) in the absence of BVAB2 and Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.

<sup>f</sup> Atopobium vaginae CCUG 48515 was tested at ~ 12× near cut-off concentration (4.0×10<sup>6</sup> CFU/mL) in the absence of BVAB2 and Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.

<sup>g</sup> Atopobium novel species CCUG 55226 was tested at ~ 6× near cut-off concentration (2.0×10<sup>6</sup> CFU/mL) in the absence of BVAB2 and Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.

h Atopobium vaginae CCUG 44125 was tested at ~ 4× near cut-off concentration (10,000 CFU/mL) in the presence of BVAB2 and/ or Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.

- i Atopobium vaginae CCUG 44156 was tested at ~ 6× near cut-off concentration (17,000 CFU/mL) in the presence of BVAB2 and/ or Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.
- i Atopobium vaginae CCUG 48515 was tested at ~ 6× (17,000 CFU/mL) to ~ 7× (20,000 CFU/mL) near cut-off concentration in the presence of BVAB2 and/or Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.
- k Atopobium novel species CCUG 55226 was tested at ~ 4× near cut-off concentration (10,000 CFU/mL) in the presence of BVAB2 and/or Megasphaera-1 to obtain 3 of 3 BV POSITIVE result calls.
- <sup>1</sup> Candida albicans ATCC 38289 was tested at ~ 4× LoD (120 CFU/mL) to obtain 3 of 3 Candida group DETECTED result calls.
- m Candida albicans ATCC 62376 was tested at ~ 20× LoD (600 CFU/mL) to obtain 3 of 3 Candida group DETECTED result calls.
- n Candida albicans ATCC 753 was tested at ~ 20× LoD (600 CFU/mL) to obtain 3 of 3 Candida group DETECTED result calls.

metronidazole-resistant strain

### 20.3 Analytical Specificity (Cross-reactivity)

The analytical specificity of the Xpert Xpress MVP test was evaluated by testing a panel of 115 potentially cross-reactive microorganisms that are likely to be found in the vaginal flora/female genital tract. All strains were tested in triplicates in simulated vaginal swab matrix at a concentration of at least  $10^6$  CFU/mL,  $10^5$  cells/mL,  $10^5$  TCID<sub>50</sub>/mL, or  $10^4$  International Unit (IU)/mL. No cross-reactivity was observed for 112 of the 115 microorganisms tested with the Xpert Xpress MVP test at the concentrations listed in Table 26. *Trichomonas tenax* and *Pentatrichomonas hominis* tested at  $1 \times 10^5$  cells/mL reported **TV DETECTED** with the Xpert Xpress MVP test. *Candida orthopsilosis* tested at  $1 \times 10^6$  CFU/mL reported Candida group **DETECTED** with the Xpert Xpress MVP test. All three initially cross-reactive organisms were negative on retest at lower concentrations. The results are presented in Table 27. This is addressed in Section 17.

Organism	Concentration	Organism	Concentration	
Bacte	ria	Bacter	Bacteria	
Acinetobacter baumannii	1×10 <sup>6</sup> CFU/mL	Mycoplasma genitalium	1×10 <sup>6</sup> CFU/mL	
Acinetobacter calcoaceticus	1×10 <sup>6</sup> CFU/mL	Mycoplasma hominis	1×10 <sup>6</sup> CFU/mL	
Actinomyces israelii	1×10 <sup>6</sup> CFU/mL	Neisseria gonorrhoeae	1×10 <sup>6</sup> CFU/mL	
Actinomyces pyogenes	1×10 <sup>6</sup> CFU/mL	Olsenella uli	1×10 <sup>6</sup> CFU/mL	
Aerococcus viridans	1×10 <sup>6</sup> CFU/mL	Pantoea agglomerans	1×10 <sup>6</sup> CFU/mL	
Alcaligenes faecalis	1×10 <sup>6</sup> CFU/mL	Peptoniphilus asaccharolyticus	1×10 <sup>6</sup> CFU/mL	
Anaerococcus tetradius	1×10 <sup>6</sup> CFU/mL	Peptoniphilus anaerobius	1×10 <sup>6</sup> CFU/mL	
Atopobium minutum	1×10 <sup>6</sup> CFU/mL	Peptostreptococcus anaerobius	1×10 <sup>6</sup> CFU/mL	
Atopobium parvulum	1×10 <sup>6</sup> CFU/mL	Plesiomonas shigelloides	1×10 <sup>6</sup> CFU/mL	
Atopobium rimae	1×10 <sup>6</sup> CFU/mL	Porphyromonas asaccharolytica	1×10 <sup>6</sup> CFU/mL	
Bacillus subtilis	1×10 <sup>6</sup> CFU/mL	Prevotella bivia	1×10 <sup>6</sup> CFU/mL	
Bacteroides caccae	1×10 <sup>6</sup> CFU/mL	Prevotella melaninogenica	1×10 <sup>6</sup> CFU/mL	
Bacteroides fragilis	1×10 <sup>6</sup> CFU/mL	Prevotella oralis	1×10 <sup>6</sup> CFU/mL	
Bacteroides stercoris	1×10 <sup>6</sup> CFU/mL	Propionibacterium acnes	1×10 <sup>6</sup> CFU/mL	
Bacteroides ureolyticus	1×10 <sup>6</sup> CFU/mL	Proteus mirabilis	1×10 <sup>6</sup> CFU/mL	
Bifidobacterium adolescentis	1×10 <sup>6</sup> CFU/mL	Providencia stuartii	1×10 <sup>6</sup> CFU/mL	

Organism	Concentration	Organism	Concentration
Bifidobacterium breve	1×10 <sup>6</sup> CFU/mL	Pseudomonas aeruginosa	1×10 <sup>6</sup> CFU/mL
Bifidobacterium longum	1×10 <sup>6</sup> CFU/mL	Salmonella typhimurium	1×10 <sup>6</sup> CFU/mL
Brevibacterium linens	1×10 <sup>6</sup> CFU/mL	Serratia marcescens	1×10 <sup>6</sup> CFU/mL
Burkholderia cepacian	1×10 <sup>6</sup> CFU/mL	Shigella flexneri	1×10 <sup>6</sup> CFU/mL
BVAB1	1×10 <sup>6</sup> copies/mL	Sneathia amnii	1×10 <sup>6</sup> CFU/mL
Campylobacter jejuni	1×10 <sup>6</sup> CFU/mL	Sneathia sanguinegens	1×10 <sup>6</sup> CFU/mL
Chlamydia trachomatis	1×10 <sup>6</sup> CFU/mL	Staphylococcus aureus	1×10 <sup>6</sup> CFU/mL
Citrobacter freundii	1×10 <sup>6</sup> CFU/mL	Staphylococcus epidermidis	1×10 <sup>6</sup> CFU/mL
Clostridium perfringens	1×10 <sup>6</sup> CFU/mL	Streptococcus agalactiae	1×10 <sup>6</sup> CFU/mL
Corynebacterium genitalium	1×10 <sup>6</sup> CFU/mL	Streptococcus mitis	1×10 <sup>6</sup> CFU/mL
Dialister micraerophilus	1×10 <sup>6</sup> CFU/mL	Streptococcus mutans	1×10 <sup>6</sup> CFU/mL
Eikenella corrodens	1×10 <sup>6</sup> CFU/mL	Streptococcus salivarius	1×10 <sup>6</sup> CFU/mL
Enterobacter aerogenes	1×10 <sup>6</sup> CFU/mL	Treponema pallidum	1×10 <sup>6</sup> copies/mL
Enterococcus faecalis	1×10 <sup>6</sup> CFU/mL	Veillonella atypica	1×10 <sup>6</sup> CFU/mL
Enterococcus faecium	1×10 <sup>6</sup> CFU/mL	Veillonella parvula	1×10 <sup>6</sup> CFU/mL
Erysipelothrix rhusiopathiae	1×10 <sup>6</sup> CFU/mL	Vibrio parahaemolyticus	1×10 <sup>6</sup> CFU/mL
Escherichia coli	1×10 <sup>6</sup> CFU/mL	Yersinia enterocolitica	1×10 <sup>6</sup> CFU/mL
Finegoldia magna	1×10 <sup>6</sup> CFU/mL	Yeas	sts
Fusobacterium nucleatum	1×10 <sup>6</sup> CFU/mL	Candida catenulate	1×10 <sup>6</sup> CFU/mL
Gardnerella vaginalis	1×10 <sup>6</sup> CFU/mL	Candida famata	1×10 <sup>6</sup> CFU/mL
Gemella haemolysans	1×10 <sup>6</sup> CFU/mL	Candida haemulonii	1×10 <sup>6</sup> CFU/mL
Kingella denitrificans	1×10 <sup>6</sup> CFU/mL	Candida inconspicua	1×10 <sup>6</sup> CFU/mL
Klebsiella pneumoniae	1×10 <sup>6</sup> CFU/mL	Candida intermedia	1×10 <sup>6</sup> CFU/mL
Kocuria rhizophila	1×10 <sup>6</sup> CFU/mL	Candida kefyr	1×10 <sup>6</sup> CFU/mL
Lactobacillus acidophilus	1×10 <sup>6</sup> CFU/mL	Candida lusitaniae	1×10 <sup>6</sup> CFU/mL
Lactobacillus crispatus	1×10 <sup>6</sup> CFU/mL	Candida norvegica	1×10 <sup>6</sup> CFU/mL
Lactobacillus gasseri	1×10 <sup>6</sup> CFU/mL	Candida rugosa	1×10 <sup>6</sup> CFU/mL
Lactobacillus helveticus	1×10 <sup>6</sup> CFU/mL	Candida utilis	1×10 <sup>6</sup> CFU/mL
Lactobacillus iners	1×10 <sup>6</sup> CFU/mL	Kodamaea ohmeri <sup>a</sup>	1×10 <sup>6</sup> CFU/mL
Lactobacillus jensenii	1×10 <sup>6</sup> CFU/mL	Pichia fermentans	1×10 <sup>6</sup> CFU/mL
Lactobacillus johnsonii	1×10 <sup>6</sup> CFU/mL	Pichia norvegensis <sup>b</sup>	1×10 <sup>6</sup> CFU/mL
Lactobacillus vaginalis	1×10 <sup>6</sup> CFU/mL	Pichia occidentalis <sup>c</sup>	1×10 <sup>6</sup> CFU/mL

Organism	Concentration	Organism	Concentration
Legionella pneumophila	1×10 <sup>6</sup> CFU/mL	Saccharomyces cerevisiae	1×10 <sup>6</sup> CFU/mL
Mageeibacillus indolicus <sup>d</sup>	1×10 <sup>6</sup> CFU/mL	Viru	ses
Megasphaera-2	1×10 <sup>6</sup> copies/mL	Hepatitis B virus	1×10 <sup>5</sup> IU/mL
Megasphaera elsdenii	1×10 <sup>6</sup> CFU/mL	Hepatitis C virus	1×10 <sup>5</sup> IU/mL
Mobiluncus curtisii	1×10 <sup>6</sup> CFU/mL	Herpes simplex virus I	1×10 <sup>5</sup> TCID <sub>50</sub> /mL
Mobiluncus mulieris	1×10 <sup>6</sup> CFU/mL	HIV-1	3×10 <sup>4</sup> IU/mL <sup>e</sup>
Moraxella catarrhalis	1×10 <sup>6</sup> CFU/mL	Human herpesvirus 2	1×10 <sup>5</sup> TCID <sub>50</sub> /mL
Morganella morganii	1×10 <sup>6</sup> CFU/mL	Human papilloma virus	4.3×10 <sup>5</sup> cells/mL
Mycobacterium smegmatis	1×10 <sup>6</sup> CFU/mL	Varicella-zoster virus	1×10 <sup>5</sup> copies/mL

<sup>a</sup> Kodamaea ohmeri is also reported as Pichia ohmeri and Candida guilliermondii.

<sup>b</sup> Pichia norvegensis is also reported as Candida norvegensis.

<sup>c</sup> Pichia occidentalis is also reported as Issatchenkia occidentalis and Candida sorbose.

<sup>d</sup> Mageeibacillus indolicus is formerly named BVAB3.

e Evaluated at highest concentration available

#### Table 27. Organisms Tested that Showed Cross-Reactivity

Organism	Concentration	Replicates correctly reported results/ Total replicates
	1×10 <sup>6</sup> CFU/mL	0/3
Candida orthopsilosis	1×10 <sup>3</sup> CFU/mL	0/3
	1×10 <sup>2</sup> CFU/mL	3/3
Pentatrichomonas hominis	1×10 <sup>5</sup> cells/mL	0/3
rentationomonas nominis	5×10 <sup>4</sup> cells/mL	3/3
	1×10 <sup>5</sup> cells/mL	0/3
Trichomonas tenax	1×10 <sup>2</sup> cells/mL	2/3
	10 cells/mL	3/3

### 20.4 Microbial Interference

An interfering microorganism study was performed to assess the inhibitory effects of microorganisms that may be encountered in vaginal specimens on the performance of Xpert Xpress MVP. Thirteen microorganisms were tested for potential interference at  $\geq 10^6$  CFU/mL for bacteria and at  $\geq 10^4$  International Unit/mL or cells/mL for viruses (Table 28). Each of the microorganisms was tested in simulated vaginal swab matrix in the presence and absence of *Atopobium vaginae* at 3× near cut-off concentrations, *Megasphaera*-1 and BVAB2 targets each at ~1.5× near cut-off concentrations, and *Candida albicans*, *C. glabrata* and *Trichomonas vaginalis* targets each at 3× LoD. The results showed that the presence of the tested microorganisms did not interfere with the performance of the Xpert Xpress MVP test.

Microorganism
Dialister micraerophilus
Gardnerella vaginalis
Lactobacillus crispatus
Lactobacillus jensenii
Lactobacillus iners
Mageeibacillus indolicus
Mobiluncus curtisii
Porphyromonas asaccharolytica
Prevotella bivia
Sneathia amnii
Streptococcus agalactiae
HIV-1 <sup>a</sup>
Human papilloma virus <sup>b</sup>

### Table 28. Potentially Interfering Microorganisms Tested

<sup>a</sup> Evaluated at highest concentration available (3×10<sup>4</sup> IU/mL)

<sup>b</sup> Evaluated at 1×10<sup>4</sup> cells/mL

### 20.5 Competitive Interference

Competitive interference between targets (BV, Candida group, Candida glab-krus and TV) of the Xpert Xpress MVP test caused by co-infections was evaluated by testing each target at low positive concentration in the presence of another target at high concentration in simulated vaginal swab matrix. Competitive inhibitory effects between the BV analytes (Atop gp and Mega1-BVAB2) were also evaluated in simulated vaginal swab matrix. The conditions simulating co-infections were presented in Table 29. Under the conditions of this study, competitive inhibitory effects were not observed between MVP targets or BV analytes with the Xpert Xpress MVP test.

			Competitive
	Testing Panel	Testing Target/Organisms (Low Positive)	Competitive Target/Organisms (High Positive)
	1	Atopobium vaginae	Candida albicans (1×10 <sup>6</sup> CFU/mL)
Competitive Interference Evaluation between MVP Targets	2	(< 3× near cut-off concentration) and BVAB2	<i>Candida glabrata</i> (1×10 <sup>6</sup> CFU/mL)
	3	(< 3× near cut-off concentration)	Trichomonas vaginalis

### Table 29. Competitive Interference Testing Conditions

(1×10<sup>5</sup> cells/mL)

Testing Panel	Testing Target/Organisms (Low Positive)	Competitive Target/Organisms (High Positive)
4	Atopobium vaginae	Candida albicans (1×10 <sup>6</sup> CFU/mL)
5	(< 3× near cut-off concentration) and <i>Megasphaera</i> -1	<i>Candida glabrata</i> (1×10 <sup>6</sup> CFU/mL)
6	(< 3× near cut-off concentration)	<i>Trichomonas vaginalis</i> (1×10 <sup>5</sup> cells/mL)
7	<i>Atopobium vaginae</i> (< 3× near cut-off concentration),	<i>Candida albicans</i> (1×10 <sup>6</sup> CFU/mL)
8	BVAB2 (< 1.5× near cut-off concentration)	<i>Candida glabrata</i> (1×10 <sup>6</sup> CFU/mL)
9	and <i>Megasphaera</i> -1 (< 1.5× near cut-off concentration)	<i>Trichomonas vaginalis</i> (1×10 <sup>5</sup> cells/mL)
10	Atopobium vaginae	<i>Candida albicans</i> (1×10 <sup>6</sup> CFU/mL)
11	(< 3× near cut-off concentration) in the absence of BVAB2 and	<i>Candida glabrata</i> (1×10 <sup>6</sup> CFU/mL)
12	Megasphaera-1	<i>Trichomonas vaginalis</i> (1×10 <sup>5</sup> cells/mL)
13		Atopobium vaginae (1×10 <sup>7</sup> CFU/mL), BVAB2 (1×10 <sup>7</sup> copies/mL) and <i>Megasphaera</i> -1 (1×10 <sup>7</sup> copies/mL)
14	Candida albicans (< 3× LoD)	Atopobium vaginae (1×10 <sup>7</sup> CFU/mL) in the absence of BVAB2 and <i>Megasphaera</i> -1
15		<i>Candida glabrata</i> (1×10 <sup>6</sup> CFU/mL)
16		<i>Trichomonas vaginalis</i> (1×10 <sup>5</sup> cells/mL)

esting Panel	Testing Target/Organisms (Low Positive)	Competitive Target/Organisms (High Positive)
17		Atopobium vaginae (1×10 <sup>7</sup> CFU/mL), BVAB2 (1×10 <sup>7</sup> copies/mL) and <i>Megasphaera</i> -1 (1×10 <sup>7</sup> copies/mL)
18	Candida glabrata (< 3× LoD)	Atopobium vaginae (1×10 <sup>7</sup> CFU/mL) in the absence of BVAB2 and <i>Megasphaera</i> -1
19		Candida albicans (1×10 <sup>6</sup> CFU/mL)
20		<i>Trichomonas vaginalis</i> (1×10 <sup>5</sup> cells/mL)
21		Atopobium vaginae (1×10 <sup>7</sup> CFU/mL), BVAB2 (1×10 <sup>7</sup> copies/mL) and <i>Megasphaera</i> -1 (1×10 <sup>7</sup> copies/mL)
22	Trichomonas vaginalis (< 3× LoD)	<i>Atopobium vaginae</i> (1×10 <sup>7</sup> CFU/mL) in the absence of BVAB2 and <i>Megasphaera</i> -1
23		<i>Candida albicans</i> (1×10 <sup>6</sup> CFU/mL)
24		Candida glabrata (1×10 <sup>6</sup> CFU/mL)

	Testing Panel	Testing Target/Organisms (Low Positive)	Competitive Target/Organisms (High Positive)
Competitive Interference Evaluation between BV Organisms	25	<i>Atopobium vaginae</i> (< 3× near cut-off concentration)	BVAB2 (1×10 <sup>7</sup> copies/mL) and <i>Megasphaera</i> -1 (1×10 <sup>7</sup> copies/mL)
	26	BVAB2 (< 3× near cut-off concentration)	<i>Atopobium vaginae</i> (1×10 <sup>6</sup> CFU/mL)
	27	<i>Megasphaera</i> -1 (< 3× near cut-off concentration)	<i>Atopobium vaginae</i> (1×10 <sup>6</sup> CFU/mL)
	28	BVAB2 (< 1.5× near cut-off concentration) and <i>Megasphaera</i> -1 (< 1.5× near cut-off concentration)	<i>Atopobium vaginae</i> (1×10 <sup>6</sup> CFU/mL)

### 20.6 Potentially Interfering Substances

Twenty substances that may be present in the vaginal swab specimens with the potential to interfere with the performance of Xpert Xpress MVP were evaluated. The potentially interfering substances included prescription and over-the-counter drugs, creams and/or gels, blood, hormones, semen and mucus. The substances, active ingredients, and concentrations tested are listed in Table 30. Potential interferents were tested in simulated vaginal swab matrix in the presence and absence of Xpert Xpress MVP targets at 3× LoD/3× near cut-off concentrations. With the exception of the 5.5% concentration of mucin (from porcine stomach), no clinically significant inhibitory effects from substances that may be encountered in vaginal specimens were observed on the performance of the Xpert Xpress MVP test. When mucin was tested at a concentration of 4.0%, no clinically significant inhibitory effect was observed on the performance of the Xpert Xpress MVP test. This is addressed in Section 17.

Substance/Class	Active Ingredient	Concentration Tested				
Blood	Blood	5.0% v/v				
Seminal Fluid	Semen	5.0% v/v				
		5.5% v/v (Interference Observed)				
Mucus	Mucin (porcine stomach)	4.0% v/v (Interference not Observed)				
Leukocytes	Leukocytes	10 <sup>5</sup> cells/mL				
Intravaginal Hormones	Estradiol; Progesterone	7mg/mL Progesterone + 0.07mg/mL Beta Estradiol				
Over the counter (OTC)	Benzocaine 5%; Resorcinol 2%	0.25% w/v				
Vaginal Products;	Clotrimazole 2%	0.25% w/v				
Contraceptives;	Miconazole Nitrate 4%	0.25% w/v				
Vaginal treatments	Tioconazole 6.5%	0.25% w/v				

Substance/Class	Active Ingredient	<b>Concentration Tested</b>
	5% w/w acyclovir	0.25% w/v
	Glycerin, Propylene glycol	0.25% w/v
	Glycerin; carbomer	0.25% w/v
	Glycerin; sodium hydroxide; carbomer	0.25% w/v
	Glycerin, Hydroxyethyl cellulose	0.25% w/v
	Berberis Vulgaris 6X HPUS (Barberry), Borax 3X HPUS (Sodium Borate), Collinsonia Canadensis 3X HPUS (Stone Root), Hamamelis Virginiana 6X HPUS (Witch Hazel), <i>Bacillus coagulans</i> (Lactospore <sup>®</sup> )	0.25% w/v
	Povidone-iodine 10% (topical)	0.25% v/v
	Povidone-iodine 0.3% (douche)	0.25% v/v
	Nonoxynol-9 12.5%	0.25% w/v
	Metronidazole 0.75%	0.25% w/v
Hemorrhoidal Cream	Glycerin 14%; Pramoxine HCl 1%	0.25% w/v

### 20.7 Carry-over Contamination

A study was conducted to demonstrate that single-use, self-contained GeneXpert cartridges prevent specimen and amplicon carry-over contamination from very high titer positive samples into successively run negative samples when processed in the same GeneXpert module. The study consisted of a negative sample processed in the same GeneXpert module immediately after processing a very high BV positive sample (an *A. vaginae* strain at  $2.8 \times 10^7$  CFU/mL and BVAB2 plasmid DNA at  $5.0 \times 10^8$  copies/mL), a very high Candida group sample (a *C. albicans* strain at  $3.0 \times 10^6$  CFU/mL), or a very high TV sample (a *T. vaginalis* strain at  $5.0 \times 10^6$  cells/mL) in simulated vaginal swab matrix. The testing scheme was repeated 20 times in a single GeneXpert module for a total of 41 runs (20 high positive samples and 21 negative samples per module) across 3 GeneXpert modules. There was no evidence of any carry-over contamination. All 63 negative samples were correctly reported as negative/not detected. All 60 positive samples were correctly reported as positive/detected.

## 21 Reproducibility

Reproducibility and precision of the Xpert Xpress MVP test was established through a multicenter (3 sites), blinded study utilizing a multi-factor nested design consisting of contrived panel members spanning the relevant limit of detection (LoD) spectrum (or, in the case of BV, the near cut-off concentration) for the 4 intended target types.

A panel of ten panel members with varying concentrations of the intended target types were tested by two operators in duplicate on six different days at three sites using three lots of Xpert Xpress MVP test cartridges. The total number of tests for each panel member was 144 (3 sites  $\times$  3 lots  $\times$  2 days  $\times$  2 operators  $\times$  2 runs  $\times$  2 replicates). The three concentrations for each intended target type included two positive levels (moderate positives at  $\sim$ 3 $\times$  LoD/near cut-off concentration, low positives at  $\sim$ 1 $\times$  LoD/near cut-off concentration) and one negative. For the BV target, a high negative level (<1 $\times$  near the cut-off concentration) was also included.

Percent agreement for each panel member was analyzed across each of the 6 operators and across each of the 3 sites. Overall percent agreement for each panel member was calculated, as well as the Wilson Score 95% confidence interval for each proportion of concordance (Table 31).

Panel		Site 01			Site 02			Site 03		Overall
member	Op 1	Op 2	Subtotal	Op 1	Op 2	Subtotal	Op 1	Op 2	Subtotal	Agreement and 95% CI
Negative	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (144/144) 97.4% - 100%
BV, High Neg	66.7% (16/24)	83.3% (20/24)	75.0% (36/48)	41.7% (10/24)	62.5% (15/24)	52.1% (25/48)	54.2% (13/24)	45.8% (11/24)	50.0% (24/48)	59.0% (85/144) 50.9% - 66.7%
BV, Low Pos	91.7% (22/24)	100% (24/24)	95.8% (46/48)	95.8% (23/24)	95.8% (23/24)	95.8% (46/48)	100% (24/24)	100% (24/24)	100% (48/48)	97.2% (140/144) 93.1% - 98.9%
BV, Mod Pos	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (144/144) 97.4% - 100%
<i>C. albicans</i> , Low Pos	95.8% (23/24)	100% (24/24)	97.9% (47/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	99.3% (143/144) 96.2% - 99.9%
<i>C. albicans</i> , Mod Pos	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (144/144) 97.4% - 100%
<i>C. glabrata</i> , Low Pos	100% (24/24)	100% (24/24)	100% (48/48)	95.8% (23/24)	100% (24/24)	97.9% (47/48)	100% (24/24)	100% (24/24)	100% (48/48)	99.3% (143/144) 96.2% - 99.9%
<i>C. glabrata</i> , Mod Pos	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (144/144) 97.4% - 100%
TV, Low Pos	95.8% (23/24)	95.8% (23/24)	95.8% (46/48)	91.7% (22/24)	95.8% (23/24)	93.8% (45/48)	87.5% (21/24)	100% (24/24)	93.8% (45/48)	94.4% (136/144) 89.4% - 97.2%
TV, Mod Pos	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (24/24)	100% (24/24)	100% (48/48)	100% (144/144) 97.4% - 100%

#### Table 31. Summary of Reproducibility and Precision Results

Abbreviations: Mod, moderate; Neg, negative; Op, operator; Pos, positive

The reproducibility of the Xpert Xpress MVP test was also evaluated in terms of the fluorescence signal expressed in Ct values for each target detected. The mean, standard deviation (SD), and coefficient of variation (CV) between-sites, between-lots, between-days, between-operators, between-runs and within-run for each panel member are presented in Table 32.

Panel	Analuta	N <sup>a</sup>	Mean	Si	te	L	ot	Da	ay	Ope	rator	Betw R	een- un	Withi	n-run	То	tal
Member	Analyte	N"	Ct	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
Negative	SPC	144	32.66	0.06	0.2	0.17	0.5	0	0	0.24	0.7	0	0	0.37	1.1	0.48	1.5
BV, High Neg		144	32.45	0.07	0.2	0.17	0.5	0	0	0.12	0.4	0.05	0.2	0.28	0.9	0.36	1.1
BV, Low Pos	Atop gp	144	31.95	0.03	0.1	0.19	0.6	0	0	0	0	0.27	0.8	0.51	1.6	0.61	1.9
BV, Mod Pos		144	30.56	0	0	0.20	0.7	0.13	0.4	0.10	0.3	0.14	0.4	0.30	1.1	0.42	1.4
BV, High Neg		111	41.08	0.26	0.6	0.27	0.7	0	0	0.35	0.9	0	0	1.28	3.1	1.38	3.4
BV, Low Pos	Mega1- BVAB2	144	36.31	0	0	0.31	0.9	0	0	0	0	0.23	0.6	0.58	1.6	0.70	1.9
BV, Mod Pos		144	35.25	0.16	0.5	0.19	0.5	0.19	0.5	0	0	0	0	0.59	1.7	0.67	1.9
C. albicans, Low Pos	0	144	36.67	0	0	0.22	0.6	0	0	0.19	0.5	0.56	1.5	0.78	2.1	1.01	2.7
C. albicans, Mod Pos	Cgroup	144	35.00	0.27	0.8	0	0	0	0	0.60	1.7	0.45	1.3	0.55	1.6	0.96	2.8
C. glabrata, Low Pos	Cglab-	143	31.79	0	0	0.35	1.1	0	0	0	0	0.37	1.2	1.35	4.2	1.44	4.5
C. glabrata, Mod Pos	krus	144	29.75	0.54	1.8	0.22	0.8	0.34	1.1	0.47	1.6	0.07	0.2	0.90	3.0	1.22	4.1
TV, Low Pos	τv	136	38.41	0.21	0.6	0.22	0.6	0	0	0.33	0.9	0	0	1.23	3.2	1.30	3.4
TV, Mod Pos	ιv	144	35.97	0.15	0.4	0.09	0.3	0	0	0.07	0.2	0.23	0.6	0.50	1.4	0.58	1.6

<sup>a</sup> Number of samples with Ct values out of 144.

Abbreviations: Atop gp, Atopobium group; Cglab-krus, *C. glabrata/C. krusei*; Cgroup, *Candida* spp.; CV, coefficient of variance; Mega1; *Megasphaera*-1; Mod, moderate; Neg, negative; Pos, positive; SD, standard deviation; SPC; sample processing control

**Note** The variance estimate from some factors may be numerically negative, which can occur if the variability due to those factors is very small. When this occurs, the variability as measured with SD and CV is set to 0.

### 21.1 Precision of the BV Target

Due to the diversity of organisms associated with the detection of BV, a separate single-site study was conducted to establish precision of the BV target. To establish the test precision for the BV targets in the Xpert Xpress MVP test, a single-center, blinded precision study was conducted utilizing samples with unique combinations of contrived BV organisms.

A panel of nine panel members were tested by two operators in duplicate on ten different days using one lot of Xpert Xpress MVP test cartridges. The total number of tests for each panel member was 80 (1 site  $\times$  1 lot  $\times$  10 days  $\times$  2 operators  $\times$  2 runs  $\times$  2 replicates). The panel included 1 negative panel member, a high negative level (<1 $\times$  the near cut-off concentration), and two positive levels (low positives at  $\sim$ 1 $\times$  the near cut-off concentration, and moderate positives at  $\sim$ 3 $\times$  the near cut-off concentration) utilizing unique combinations of the BV organisms (*Atopobium vaginae, Megasphaera*-1, and BVAB2).

As shown in Table 33, agreement for each panel member was calculated, as well as the Wilson Score 95% confidence interval for each proportion of concordance.

Sample Type	Overall Agreement	95% CI
Negative	100% (80/80)	95.4% - 100%
A. vaginae, Low positive	97.5% (78/80)	91.3% - 99.3%
A. vaginae and BVAB2, High negative	66.3% (53/80)	55.4% - 75.7%
A. vaginae and BVAB2, Low positive	97.5% (78/80)	91.3% - 99.3%
A. vaginae and Megasphaera-1, High negative	23.8% (19/80)	15.8% - 34.1%
A. vaginae and Megasphaera-1, Low positive	95.0% (76/80)	87.8% - 98.0%
A. vaginae, BVAB2, and Megasphaera-1, High negative	53.8% (43/80)	42.9% - 64.3%
A. vaginae, BVAB2, and Megasphaera-1, Low positive	96.3% (77/80)	89.5% - 98.7%
A. vaginae, BVAB2, and Megasphaera-1, Moderate positive	100% (80/80)	95.4% - 100%

#### Table 33. Summary of Precision Results for the BV Target

Abbreviations: A. vaginae; Atopobium vaginae

Precision for BV targets was evaluated in terms of the fluorescence signal expressed in Ct values for each target detected. The mean, standard deviation (SD), and coefficient of variation (CV) between-days, between-operators, between-runs and within-run for each panel member are presented in Table 34.

Panel member	Analyte	a	a Mean		Day		Operator		Between-Run		Within-run		Total	
Fanermeniber	Analyte	N <sup>a</sup>	Ct	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	
Negative	SPC	80	32.84	0.00	0.0	0.49	1.5	0.22	0.7	0.90	2.7	1.05	3.2	
<i>A. vaginae</i> , Low Pos	Atop gp	80	24.98	0.00	0.0	0.00	0.0	0.03	0.1	0.32	1.3	0.32	1.3	
	SPC	80	32.64	0.17	0.5	0.17	0.5	0.12	0.4	0.37	1.1	0.46	1.4	
A. vaginae and BVAB2.	Atop gp	80	32.35	0.00	0.0	0.16	0.5	0.00	0.0	0.20	0.6	0.26	0.8	
High Neg	Mega1- BVAB2 <sup>b</sup>	75	41.30	0.37	0.9	0.00	0.0	0.26	0.6	1.15	2.8	1.24	3.0	
	Atop gp	80	32.20	0.00	0.0	0.04	0.1	0.08	0.3	0.22	0.7	0.24	0.7	
<i>A. vaginae</i> and BVAB2, Low Pos	Mega1- BVAB2 <sup>b</sup>	80	40.03	0.00	0.0	0.00	0.0	0.30	0.7	0.90	2.2	0.94	2.4	

Panel member	Analyta	a	Mean	D	ay	Оре	rator	Betwe	en-Run	With	in-run	Тс	otal
Panel member	Analyte	N <sup>a</sup>	Ct	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)	SD	CV (%)
	SPC	80	32.63	0.11	0.3	0.17	0.5	0.00	0.0	0.39	1.2	0.44	1.3
A. vaginae and Mega-1,	Atop gp	80	32.62	0.00	0.0	0.04	0.1	0.00	0.0	0.33	1.0	0.34	1.0
High Neg	Mega1- BVAB2 <sup>b</sup>	28	38.98	0.00	0.0	1.01	2.6	0.21	0.6	0.84	2.2	1.33	3.4
A. vaqinae	Atop gp	79	32.07	0.00	0.0	0.15	0.5	0.18	0.6	0.41	1.3	0.47	1.5
and Mega-1, Low Pos	Mega1- BVAB2 <sup>b</sup>	80	35.48	0.00	0.0	0.29	0.8	0.00	0.0	0.71	2.0	0.77	2.2
<b>.</b> .	SPC	80	32.74	0.15	0.5	0.12	0.4	0.17	0.5	0.33	1.0	0.41	1.3
<i>A. vaginae</i> , BVAB2, and	Atop gp	80	32.53	0.00	0.0	0.15	0.5	0.00	0.0	0.22	0.7	0.27	0.8
Mega-1, High Neg	Mega1- BVAB2 <sup>b</sup>	63	41.57	0.30	0.7	0.00	0.0	0.39	0.9	1.02	2.5	1.13	2.7
A. vaginae,	Atop gp	79	31.81	0.00	0.0	0.22	0.7	0.28	0.9	1.16	3.6	1.21	3.8
BVAB2, and Mega-1, Low Pos	Mega1- BVAB2 <sup>b</sup>	80	36.25	0.15	0.4	0.00	0.0	0.10	0.3	0.69	1.9	0.71	2.0
A. vaginae,	Atop gp	80	30.67	0.13	0.4	0.09	0.3	0.00	0.0	0.33	1.1	0.37	1.2
BVAB2, and Mega-1, Mod Pos	Mega1- BVAB2 <sup>b</sup>	80	35.64	0.00	0.0	0.26	0.7	0.00	0.0	0.48	1.3	0.54	1.5

a Number of samples with non-zero Ct values out of 80.

<sup>b</sup> Samples with Mega1-BVAB2 that did not generate a Ct value were excluded from analysis.

Abbreviations: Atop gp, Atopobium group; CV, coefficient of variance; Mega1, Megasphaera-1; Mod; moderate; Neg, negative; Pos, positive; SD, standard deviation; SPC, sample processing control

**Note** The variance estimate from some factors may be numerically negative, which can occur if the variability due to those factors is very small. When this occurs, the variability as measured with SD and CV is set to 0.

The BV-associated organisms targeted by the Xpert Xpress MVP test demonstrated acceptable precision.

## 22 Bibliography

- 1. Hainer BL, Gibson MV. Vaginitis. Am Fam Physician. 2011;83(7): 807-815.
- 2. Centers for Disease Control and Prevention. *Biosafety in Microbiological and Biomedical laboratories* (refer to latest edition). http://www.cdc.gov/biosafety/publications/
- **3.** Clinical and Laboratory Standards Institute. *Protection of Laboratory Workers from Occupationally Acquired Infections; Approved Guideline*. Document M29 (refer to latest edition).
- 4. Chemical hazards determined under REGULATION (EC) No 1272/2008 OF THE EUROPEAN PARLIAMENT AND OF THE COUNCIL of 16 December 2008 (on classification, labeling and packaging of substances and mixtures amending and repealing Directives 67/548/EEC and 1999/45/EC, and amending Regulation (EC) No 1907/2006) and the Occupational Safety and Health Standards, Hazard Communication, Toxic and Hazard Substances (March 26, 2012) (29 C.F.R., pt. 1910, subpt. Z), can be referenced on the Safety Data Sheet available at www.cepheid.com and www.cepheidinternational.com under the SUPPORT tab.

## 23 Cepheid Headquarters Locations

#### **Corporate Headquarters**

Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA

Telephone: + 1 408 541 4191 Fax: + 1 408 541 4192 www.cepheid.com

### **European Headquarters**

Cepheid Europe SAS Vira Solelh 81470 Maurens-Scopont France Telephone: + 33 563 825 300 Fax: + 33 563 825 301 www.cepheidinternational.com

## 24 Technical Assistance

### **Before Contacting Us**

Collect the following information before contacting Cepheid Technical Support:

- Product name
- Lot number
- Serial number of the instrument
- Error messages (if any)
- Software version and, if applicable, Computer Service Tag Number

### **United States Technical Support**

Telephone: + 1 888 838 3222 Email: techsupport@cepheid.com

### **France Technical Support**

Telephone: + 33 563 825 319 Email: support@cepheideurope.com

Contact information for all Cepheid Technical Support offices is available on our website: www.cepheid.com/en/support/ contact-us.

# 25 Table of Symbols

Symbol	Meaning
REF	Catalog number
IVD	<i>In vitro</i> diagnostic medical device
8	Do not reuse
LOT	Batch code
i	Consult instructions for use
	Manufacturer
	Country of manufacture
Σ	Contains sufficient for <i>n</i> tests
	Expiration date
X	Temperature limitation
<b>R</b> <sub>konly</sub>	For prescription use only



Cepheid 904 Caribbean Drive Sunnyvale, CA 94089 USA



## **26 Revision History**

Description of Changes: 301-8994, Rev. E to Rev. F

**Purpose**: Updated steps in the "Materials Provided", "Preparing the Cartridge", and "External Controls" procedure. Updated the test results in Tables 13 and 14.

Section	Description of Change
4	Added aerobic vaginitis as possible cause.
5	Updated PCR assay to PCR test.
6	Added number of tests to kit name. Added CLIA-waived Instructions for Use and Quick Reference Instructions to Materials Provided list.
7, 9.1	Added "Do not open or alter any part of the used cartridge for disposal."
9.2	Added number of days and temperature limitations for storage.
9.3	Added do not use condition for missing barcode label.
12.1, 12.2	Added note that inadequate shaking of specimen transport tube can generate false negative results. Updated steps to fill pipette, release the contents in the sample chamber, and dispose of the pipette after use.
13	Updated procedure for running a test on the GeneXpert Dx System and GeneXpert Infinity System.
17	Updated age of patients evaluated from 18 years of age to 14 years of age and older. Added limitation that false negative results can occur if level is outside the BV algorithm parameters for a positive result.
19.2	Specified the number of clinician-collected (CVS) and self-collected (SVS) vaginal swabs that were tested and eligible for inclusion in the Xpert Xpress MVPstudy.
Table 6, 7, 8, 10, 11, 12, 15, 16, 17, 18, 19, 20	Removed N= values from table.
Table 13, 14	Added Overall test results row.
Table 14	Added Total test results row and updated number of replicates tested.
21	Added "The BV-associated organisms targeted by the Xpert Xpress MVP test demonstrated acceptable precision."